Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 2742. Отображено 200.
18-09-2020 дата публикации

Продукт для пероральной доставки

Номер: RU2732498C2
Принадлежит: Пфайзер Инк. (US)

Изобретение относится к композиции для пероральной доставки витаминов и минеральных веществ субъекту, содержащей витамины, минеральные вещества, ароматизаторы или вкусовые агенты, связывающее вещество, которое включает сахарный спирт, представляющий собой изомальт, и экспициенты, выбранные из прежелатинизированного крахмала и карбоксиметилцеллюлозы, где композиция может растворяться во рту указанного субъекта или может быть пережевана и проглочена указанным субъектом и где калорийность композиции составляет приблизительно 5 калорий, а твердость композиции составляет от 17 кгс до 28 кгс. 7 з.п. ф-лы, 8 пр., 10 табл.

Подробнее
07-02-2022 дата публикации

СРЕДСТВО ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ В ЛЕГКИХ

Номер: RU2765955C1

Изобретение относится к применению (3,5-ди-трет-бутил-4-гидроксифенилтиолат)трифенилолова в качестве средства для ингибирования метастазирования эпидермоидной карциномы Lewis в легких. Технический результат: антиметастатическое средство, пригодное для внутрибрюшинного введения. 1 табл.

Подробнее
18-07-2018 дата публикации

КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ

Номер: RU2016148008A
Принадлежит:

Подробнее
15-12-1952 дата публикации

Verfahren zur Herstellung peroral anwendbarer Zinnpraeparate

Номер: DE0000859347C
Принадлежит: SCHULZ OTTO FRITZ DR, SCHULZ OTTO FRITZ DR.

Подробнее
13-02-2014 дата публикации

Selective androgen receptor modulators for treating diabetes

Номер: AU2008239601B2
Принадлежит:

This invention provides use of a SARM compound or a composition comprising the same in treating a variety of diseases or conditions in a subject, including, ...

Подробнее
11-10-2012 дата публикации

SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES

Номер: CA0002832598A1
Принадлежит:

This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC.

Подробнее
30-06-2010 дата публикации

ЛЕЧЕНИЕ НАРУШЕНИЙ КОСТНОЙ ТКАНИ С ИСПОЛЬЗОВАНИЕМ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ АДРОГЕННЫХ РЕЦЕПТОРОВ

Номер: EA0000013738B1

Изобретение обеспечивает способ лечения нарушений костной ткани, например остеопороза, остеопении, увеличенной резорбции кости, перелома кости, хрупкости кости и/или потерю минеральной плотности кости (BMD), путем введения терапевтически эффективного количества селективного модулятора андрогенного рецептора (SARM), представленного структурой формул IX или XI и/или его фармацевтически приемлемой соли, гидрата, N-оксида или любой их комбинации. Изобретение также обеспечивает способ увеличения прочности кости у субъекта и способ увеличения массы кости у субъекта, включающие введение того же самого.

Подробнее
10-09-2012 дата публикации

СЕЛЕКТИВНЫЕ МОДУЛЯТОРЫ АНДРОГЕНОВОГО РЕЦЕПТОРА ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА

Номер: UA0000099609C2

Изобретение касается способа лечения болезни или состояния субъекта-человека, в котором указанная болезнь или состояние выбраны из группы непереносимости глюкозы, гиперинсулинемии и инсулинорезистентности, включающего этап введения упомянутому субъекту селективного модулятора андрогенового рецептора (SARM) формулы III.

Подробнее
30-06-2010 дата публикации

СЕЛЕКТИВНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНА ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА

Номер: EA0200970956A1
Принадлежит:

Изобретение относится к применению соединения, представляющего собой SARM, или композиции, включающей указанное соединение, для лечения различных заболеваний или состояний пациента, включая, например, диабетическое заболевание, и/или нарушений, например сердечно-сосудистого заболевания, атеросклероза, цереброваскулярного состояния, диабетической нефропатии, диабетической нейропатии и диабетической ретинопатии.

Подробнее
04-04-2013 дата публикации

COMPOSITIONS CONTAINING SPERMINE TOGETHER WITH CADAVERINE, PUTRESCINE AND/OR SPERMIDINE

Номер: WO2013045826A1
Принадлежит:

The present invention relates to novel compositions including a mixture of cadaverine, putrescine, and spermidine at a concentration of 0.3 to 0.6 nanomoles per gram of composition, said composition also including spermine at a concentration of 150 to 17,000 nanomoles per gram of composition, as well as to the uses thereof for treating a patient for diseases associated with cell hyperproliferation.

Подробнее
07-05-2019 дата публикации

Oral care compositions

Номер: US0010278906B2

An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Подробнее
06-03-2020 дата публикации

Стабилизированные композиции на основе олова (II)

Номер: RU2716134C2

Группа изобретений относится к области фармацевтики, к стоматологии, а именно к комплексу на основе ассоциированного с оловом (II) стабилизированного фосфопептидом аморфного фосфата кальция (ACP) и/или аморфного фторид-фосфата кальция (ACFP) для минерализации зубной эмали или дентина. Для этого комплекс имеет содержание ионов олова (II) по меньшей мере 1 моль олова (II) на моль фосфопептида. Также изобретение относится к способу получения комплекса, к составу для ухода за полостью рта, содержащему комплекс, к способу минерализации зубной эмали или дентина. Кроме того, изобретение относится к способу образования защитного слоя, связанного с зубной эмалью или дентином зуба, к применению комплекса в получении лекарственного средства для минерализации зубной эмали или дентина, а также к применению комплекса в получении лекарственного средства для формирования защитного слоя, связанного с зубной эмалью или дентином зуба, где слой содержит кальций и фосфат. Изобретение обеспечивает получение ...

Подробнее
22-03-2023 дата публикации

СПОСОБ КОМБИНИРОВАННОЙ ТЕРАПИИ МЕЛАНОМЫ В16 В МЕТРОНОМНОМ РЕЖИМЕ В ЭКСПЕРИМЕНТЕ

Номер: RU2792561C1

Изобретение относится к медицине, а именно к экспериментальной фармакологии, и может быть использовано для комбинированной терапии меланомы В16 в метрономном режиме в эксперименте. Самкам мышей линии С57В1/6 8 недельного возраста массой 21-22 г перевивают штамм меланомы В16. Через 48 часов после перевивки 1 раз в сутки в течение 10 дней внутрибрюшинно вводят бис(3,5-ди-трет-бутил-4-гидроксифенилтиолат) диметилолова (Ме3) в разовой дозе 45 мг/кг в комбинации с цисплатином в разовой дозе 1 мг/кг или (3,5-ди-трет-бутил-4-гидроксифенилтиолат) трифенилолова (Ме5) в разовой дозе 15 мг/кг в комбинации с цисплатином в разовой дозе 1 мг/кг. Способ обеспечивает эффективную противоопухолевую и антиметастатическую комбинированную терапию меланомы В16 в метрономном режиме в эксперименте за счет введения комбинации Ме3 с цисплатином или комбинации Ме5 с цисплатином самкам мышей линии С57В1/6. 2 табл.

Подробнее
14-02-2019 дата публикации

Номер: RU2017122594A3
Автор:
Принадлежит:

Подробнее
10-04-2006 дата публикации

СПОСОБ ОЧИЩЕНИЯ ВНУТРЕННЕЙ СРЕДЫ ОРГАНИЗМА С ПОМОЩЬЮ ЛЕКАРСТВЕННЫХ РАСТЕНИЙ И АНТИОКСИДАНТОВ И СРЕДСТВО ЭНДОЭКОЛОГИЧЕСКОЙ КОРРЕКЦИИ

Номер: RU2004131875A
Принадлежит:

... 1. Способ очищения внутренней среды организма, при котором активизируют функции естественной системы очищения организма человека, отличающийся тем, что осуществляют одновременное стимулирующее воздействие на все основные механизмы очищения внутренней среды организма: экскреторное очищение межклеточной среды, внутриклеточную биотрансформацию ксенобиотиков и антиоксидантную защиту, при этом используют для приема внутрь комплексное средство эндоэкологической коррекции на основе растительного сырья, витаминов и микроэлементов. 2. Средство эндоэкологической коррекции, отличающееся тем, что состоит из трех комплексов и включает в составе первого комплекса лекарственные растения, которые стимулируют процессы экскреторного очищения межклеточной среды и повышают детоксикационную активность иммунных клеток; в составе второго комплекса растительные, компоненты, которые стимулируют процессы внутриклеточной биотрансформации ксенобиотиков; в составе третьего комплекса растительные экстракты и антиоксиданты ...

Подробнее
30-11-2017 дата публикации

KhIMIOIMMUNOTERAPIYa, REINFORCED HAPTENS, IN THE FORM OF PERSONALIZED INTRA-TUMOR KhIMIOIMMUNOTERAPII WITH SUPER-MINIMUM CUT

Номер: EA0201791126A1
Автор:
Принадлежит:

Подробнее
30-06-2008 дата публикации

ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ, ОЖОГОВ, РАН И ПОВРЕЖДЕНИЙ СПИННОГО МОЗГА СЕЛЕКТИВНЫМИ МОДУЛЯТОРАМИ АНДРОГЕНОВОГО РЕЦЕПТОРА

Номер: EA0200800710A1
Принадлежит:

Данное изобретение обеспечивает: 1) способ лечения субъекта, страдающего от или предрасположенного к заболеванию почек или нарушению функции почек; 2) способ лечения субъекта, страдающего от раны или уменьшение частоты, или смягчение силы раны у субъекта; 3) способ лечения субъекта, страдающего от ожога или уменьшение частоты, или смягчение силы ожога у субъекта, содержащий стадию введения упомянутому субъекту соединения селективного модулятора андрогенового рецептора (SARM); 4) способ лечения субъекта, страдающего от повреждения спинного мозга, введением субъекту селективного модулятора андрогенового рецептора (SARM) и/или аналога, производного, изомера, метаболита, фармацевтически приемлемой соли, фармацевтического продукта, гидрата, N-оксила, пролекарства, полиморфа, примеси или кристаллической формы упомянутого SARM соединения или их любой комбинации.

Подробнее
12-12-2002 дата публикации

Process for the manufacture of 117Sn diethylenetriaminepentaacetic acids

Номер: US20020187975A1
Принадлежит:

Novel methods are provided for the manufacture of117mSn(Sn4+) DTPA. The method allows the use of DTPA, a toxic chelating agent, in an approximately 1:1 ratio to117mSn(Sn4+) via either aqueous conditions, or using various organic solvents, such as methylene chloride. A pharmaceutical composition manufactured by the novel method is also provided, as well as methods for treatment of bone tumors and pain associated with bone cancer using the pharmaceutical composition of the invention.

Подробнее
22-05-2017 дата публикации

СОЕДИНЕНИЯ, ОБРАЗУЮЩИЕ КОМПЛЕКСЫ

Номер: RU2619939C2
Принадлежит: СТРАТОКСЕР(С) КФТ. (HU)

Настоящее изобретение относится к соединениям, образующим комплексы, общей формулы,а также их применению и получению. Технический результат: получены новые соединения формулы (I), а также их комплексы, которые могут применяться для получения фармацевтической композиции для профилактики и лечения отравления стронцием, оловом или свинцом. 9 н. и 4 з.п. ф-лы, 9 табл., 18 пр., 13 ил.

Подробнее
09-09-2019 дата публикации

КОМПОЗИЦИЯ ДЛЯ ЧРЕСКОЖНОЙ АБСОРБЦИИ

Номер: RU2699674C1

Изобретение относится к фармацевтической промышленности, а именно к композиции для чрескожной абсорбции. Композиция для чрескожной абсорбции, включающая тестостерон, один или более органических растворителей, выбираемых из группы, состоящей из пропиленгликоля, 1,3-бутиленгликоля, дипропиленгликоля и полиэтиленгликоля, гелеобразующий агент, выбранный из группы производных целлюлозы и полимеров на основе акриловой кислоты, воду, где композиция не содержит одноатомного спирта, имеющего от 2 до 4 атомов углерода, где компоненты взяты в эффективных количествах. Предлагаемая композиция, содержащая тестостерон, эффективно распределяется за счет высокой аффинности к коже и адгезии на коже, стабильно остается на коже. 5 з.п. ф-лы, 8 табл., 49 пр.

Подробнее
30-01-2018 дата публикации

Стабилизированные композиции на основе олова (II)

Номер: RU2016126429A
Принадлежит:

Подробнее
20-07-2007 дата публикации

СПОСОБ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЧАСТИЧНОГО СНЯТИЯ ПОБОЧНЫХ ЭФФЕКТОВ ЗАМЕСТИТЕЛЬНОЙ ТЕРАПИИЭСТРОГЕНАМИ

Номер: RU2006100031A
Принадлежит:

... 1. Фармацевтическая композиция для частичного снятия патологических состояний у женщин с постклимактерическим синдромом, содержащая следующие ингредиенты: лизин, пролин, аргинин, аскорбиновую кислоту, магний, экстракт зеленого чая, N-ацетил-цистеин, селен, медь, марганец и один фармацевтически приемлемый компонент, выбранный из следующего перечня: носитель, разбавитель, наполнитель, при этом фармацевтическая композиция содержат лизин в количестве 24-25 мас.%, аскорбиновую кислоту в количестве 16-25 мас.% и экстракт зеленого чая в количестве 22-25 мас.%. 2. Фармацевтическая композиция по п.1, дополнительно содержащая эстрогенное соединение, выбранное из следующего перечня: этинил-эстроген, местранол, эстрадиол, этинил-эстрадиол, эстриол, норэтистерон, линестренол, этинодиол, диенострол, биперазин-эстрон-сульфат, фитоэстроген. 3. Фармацевтическая композиция по п.2, дополнительно содержащая прогестиновое соединение, выбранное из следующего перечня: медрокси-прогестерон, норэтилнодрел, норэтиндрон ...

Подробнее
11-02-2010 дата публикации

Regulation von Körpergewicht durch Materialien basierend auf Zitrusvariationen

Номер: DE0069638106D1
Принадлежит: JONES DENNIS, JONES, DENNIS

Подробнее
23-10-2008 дата публикации

Selective androgen receptor modulators for treating diabetes

Номер: AU2008239601A1
Принадлежит:

Подробнее
05-12-2019 дата публикации

Oral composition

Номер: AU2015276158B2
Принадлежит: Spruson & Ferguson

The present invention relates to a composition comprising an antibacterial agent in an amount insufficient to provide antibacterial effect, a physiologically acceptable divalent metal ion in a very low concentration and a physiologically acceptable polymer for preventing and/or treating halitosis, bad breath, dry mouth or sore throat.

Подробнее
05-03-2020 дата публикации

Oral care compositions

Номер: AU2019200755C1
Принадлежит: Shelston IP Pty Ltd.

An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Подробнее
23-12-2015 дата публикации

ORAL COMPOSITION

Номер: CA0002951432A1
Принадлежит:

The present invention relates to a composition comprising an antibacterial agent in an amount insufficient to provide antibacterial effect, a physiologically acceptable divalent metal ion in a very low concentration and a physiologically acceptable polymer for preventing and/or treating halitosis, bad breath, dry mouth or sore throat.

Подробнее
09-01-2014 дата публикации

SELECTIVE ANDROGEN RECEPTOR MODULATORS

Номер: US20140011774A1
Принадлежит:

This invention provides pharmaceutical compositions comprising combination of SARM compounds and antiresorptive agents such as SERM compounds, including, inter-alia, Raloxifene, and uses thereof for treating osteoporosis and associated diseases.

Подробнее
27-12-2007 дата публикации

COMPOSITION AND METHOD FOR MODULATING ADDICTIVE BEHAVIORS

Номер: US2007298057A1
Принадлежит:

Improved compositions and methods useful in the treatment and prevention of impulsive, compulsive, reward seeking, and other addictive behaviors, including applications involving the behavioral/cognitive process of assigning importance, maintaining attention, and assessing salience. The composition includes Vitex agnus-castus (Chastetree berry) extract in an effective amount for supporting and promoting a healthy lifestyle free from addictive behavior or for preventing or treating addictive behavior. Huperzine and/or 5-HTP (5-hydroxytryptophan) may also be included. The composition may also include ingredients to address nutritional deficiencies in the addict, and nutrients depleted during the withdrawal of any reinforcer that is the object of the addiction.

Подробнее
04-02-2020 дата публикации

КОМПОЗИЦИЯ РАСТВОРА ДЛЯ ПОЛОСКАНИЯ ПОЛОСТИ РТА И ЕЕ ПРИМЕНЕНИЕ

Номер: RU2713174C2
Принадлежит: МЕДА ОТС АБ (SE)

Группа изобретений относится к композиции раствора для полоскания полости рта и ее применению. Предлагаемая композиция раствора для полоскания полости рта содержит антибактериальный агент бис-бигуанид, причем указанный агент представляет собой хлоргексидин или его соль и присутствует в композиции в количестве 0,0049 масс. %, физиологически приемлемый ион двухвалентного металла, который представляет собой Zn и присутствует в композиции в количестве 0,049 масс. %, и хитозан или производное хитозана в количестве 0,1 масс. %. Предлагается применение указанной композиции для предотвращения и/или лечения галитоза, для предотвращения и/или лечения неприятного запаха изо рта, а также для предотвращения и/или лечения боли в горле. Комбинирование вышеуказанного антибактериального агента в количестве, недостаточном для обеспечения антибактериального эффекта, физиологически приемлемого иона двухвалентного металла Zn в очень низкой концентрации и физиологически приемлемого полимера хитозана обеспечивает ...

Подробнее
27-04-2007 дата публикации

СРЕДСТВО ЭНДОЭКОЛОГИЧЕСКОЙ КОРРЕКЦИИ И СПОСОБ ЭНДОЭКОЛОГИЧЕСКОЙ КОРРЕКЦИИ, ОСНОВАННЫЙ НА ЕГО ПРИМЕНЕНИИ

Номер: RU2297843C2

Изобретение относится к химико-фармацевтической промышленности, а именно к созданию средств, применяемых в экологической медицине, предназначенных для комплексного очищения внутренней среды организма от токсических веществ и вредных продуктов обмена, и может быть использовано для профилактики и коррекции функциональных расстройств и заболеваний, связанных с воздействием на организм истощающих факторов внешней среды, особенно при наличии признаков экзо- и эндогенной интоксикации. Средство эндоэкологической коррекции содержит лекарственные растения, растительные экстракты и природные антиоксиданты, которое согласно изобретению состоит из трех комплексов и включает: в составе первого комплекса лекарственные растения, которые стимулируют все системы экскреторного очищения и повышают детоксикационную активность иммунных клеток; в составе второго комплекса растительные компоненты, которые стимулируют активность ферментов биотрансформации I и II фазы, т.е. процессы внутриклеточного очищения; в ...

Подробнее
17-01-2019 дата публикации

Номер: RU2016148008A3
Автор:
Принадлежит:

Подробнее
22-12-2021 дата публикации

СРЕДСТВО ДЛЯ ИНГИБИРОВАНИЯ МЕТАСТАЗИРОВАНИЯ В ЛЕГКИХ

Номер: RU2762730C1

Изобретение относится к применению бис(3,5-ди-трет-бутил-4-гидроксифенилтиолат)диметилолова в качестве средства для ингибирования метастазирования меланомы в легких. Технический результат заключается в снижении частоты развития и количества метастазов меланомы в легких. 1 табл., 1 пр.

Подробнее
15-03-2007 дата публикации

Hypoallergene Metallaminosäure-Chelate und Zusammensetzung, die Metallaminosäure-Chelate enthalten

Номер: DE112005000909T5

Hypoallergene Metallaminosäure-Chelat-Zusammensetzung, die Metall-Aminosäure-Chelate umfasst, die im Wesentlichen frei von Allergenen sind, sodass die Verabreichung der Metallaminosäure-Chelate in einer wirksamen Menge, die einen medizinischen, kosmetischen oder Ernährungs-Effekt (-Wirkung) bei einem Patienten ergibt, keine erkennbare nachteilige allergische Reaktion hervorruft, wobei die Metallaminosäure-Chelate ein Molverhältnis zwischen einer in der Natur vorkommenden Aminosäure und einem Metall von etwa 1:1 bis etwa 4:1 aufweisen.

Подробнее
15-01-2010 дата публикации

REGULARIZATION OF BODY WEIGHT BY MATERIALS BASED ON ZITRUSVARIATIONEN

Номер: AT0000453385T
Принадлежит:

Подробнее
21-02-2019 дата публикации

Oral care compositions

Номер: AU2019200755A1
Принадлежит: Shelston IP Pty Ltd.

An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Подробнее
08-03-2018 дата публикации

Oral care compositions

Номер: AU2017281239A1
Принадлежит: Griffith Hack

An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Подробнее
23-11-2010 дата публикации

EDIBLE COMPOSITIONS WHICH ARE ADAPTED FOR USE BY A COMPANION ANIMAL

Номер: CA0002547378C
Принадлежит: THE IAMS COMPANY

Disclosed herein are a variety of embodiments of compositions and methods which are each adapted for use by a companion animal. In one embodiment, an edible composition comprising an amount of a soluble mineral component is disclosed, wherein the soluble mineral component comprises one or more minerals selected from the group consisting of zinc, manganese, tin, copper, and mixtures thereof, wherein the amount is an effective amount for use as an oral medicament. In further embodiments, a phosphate component is included. The edible compositions are advantageously companion animal foods or supplements. Further disclosed are methods selected from treating oral cavity tartar, oral cavity plaque, periodontal disease, gingivitis, breath odor and combinations thereof comprising orally administering a described composition to a companion animal.

Подробнее
03-07-2012 дата публикации

TREATING BONE-RELATED DISORDERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS

Номер: CA0002535953C
Принадлежит: GTX, INC.

This invention provides method of treating, preventing, suppressing, inhibiting, or reducing the risk of developing a bone-related disorder, for example osteoporosis, osteopenia, increased bone resorption, bone fracture, bone frailty and/or loss of bone mineral density (BMD), by administrating a therapeutically effective amount of a selective androgen receptor modulator (SARM) and/or its analogue, derivative, isomer, metabolite pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof. The invention also provides methods of decreasing fat mass (FM) and increasing lean mass, comprising administering same.

Подробнее
16-03-2007 дата публикации

Use of a formulation comprising a surfactant and a solid active element in an organostannic compound for treatment of infectious diseases e.g. AIDS, hepatitis C, tuberculosis, septicemia, onychomycosis and anemia

Номер: FR0002890565A1
Принадлежит:

Procédés relatifs à la composition, préparation et administration d'une formulation inédite pour le traitement chez l'homme et chez l'animal de maladies infectieuses, virales telles que le SIDA (syndrome immunodéficitaire acquis dés la contamination jusqu'en phase terminale) et l'hépatite C, bactériennes telles que les septicémies et la tuberculose, fongiques telles que l'onychomycose et également pour les anémies. Cette composition est un mélange spécifique d'un élément actif appartenant à certains agents tensioactifs avec un autre élément actif appartenant à certains composés organostanneux. Cette composition peut avoir différentes présentations telles en ampoules injectables, en gélules, en capsules, en suppositoires et s'administrer soit par voie parentérale, soit orale, soit rectale et soit lymphatique.

Подробнее
08-03-2007 дата публикации

TREATING RENAL DISEASE, BURNS, WOUNDS AND SPINAL CORD INJURY WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS

Номер: WO000002007027582A2
Принадлежит:

This invention provides: 1) a method of treating a subject suffering from, or predisposed to a kidney disease or disorder; 2) a method of treating a subject suffering from a wound, or reducing the incidence of, or mitigating the severity of a wound in a subject; 3) a method of treating a subject suffering from a burn, or reducing the incidence of, or mitigating the severity of a burn in a subject, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound; 4) a method of treating a subject suffering from a spinal cord injury, by administering to the subject a selective androgen receptor modulator (SARM) and/or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.

Подробнее
06-08-2013 дата публикации

Targeting cancer therapy combination

Номер: US0008501243B2
Автор: Baofa Yu, YU BAOFA
Принадлежит: YU BAOFA

Methods for treating neoplasm, tumors and cancers, using one or more tumor treating drug carriers, haptens and anticancer drugs, alone or in combination with other antineoplastic agents or treatments, are provided. Also provided are compositions, and kits containing the composition for affecting the therapy.

Подробнее
23-07-2019 дата публикации

КОМПОЗИЦИИ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА

Номер: RU2695340C1

Группа изобретений относится к области стоматологии, а именно к композиции для ухода за полостью рта с высоким содержанием воды, содержащей приемлемый для применения в полости рта носитель, фосфат цинка, фторид двухвалентного олова и буферную систему на основе органической кислоты. При этом количество фосфата цинка составляет от 0,05 вес. % до 10 вес. % относительно веса композиции для ухода за полостью рта, где количество воды составляет от 15 вес. % до 30 вес. % относительно веса композиции и где буферная система находится в количестве от 1 вес. % до 3 вес. % относительно веса композиции. Группа изобретений также относится к способу лечения или предупреждения эрозивной деминерализации зубов, способу лечения или предупреждения гингивита, способу лечения или предупреждения зубного налета, а также к способу лечения или предупреждения кариеса зубов, при этом способы предусматривают нанесение в полость рта человека, нуждающегося в этом. Группа изобретений обеспечивает улучшенную защиту от ...

Подробнее
14-02-2019 дата публикации

Препарат для пероральной доставки

Номер: RU2017122594A
Принадлежит:

Подробнее
20-02-2016 дата публикации

СОЕДИНЕНИЯ, ОБРАЗУЮЩИЕ КОМПЛЕКСЫ

Номер: RU2014130182A
Принадлежит:

... 1. Соединения общей формулыгде Rи Rявляются одинаковыми или различными группами общей формулыи их соли и/или комплексы,где n представляет собой 0, 1 или 2,Q представляет собой карбоксильную группу,X представляет собой атом кислорода, серы или азота,при этом заместитель азота представляет собой атом водорода или линейную или разветвленную C-алкильную группу;R, Rи Rявляются одинаковыми или различными группами, и представляют собой атом водорода, атом галогена или линейную или разветвленную C-алкильную группу, C-алкиленовую группу, C-алкинильную группу, арильную, аралкильную или гетероарильную группу, насыщенную или ненасыщенную циклоалкильную группу или замещенную или незамещенную гетероциклическую группу, содержащую один или несколько атомов серы, кислорода или азота, которые возможно замещены одним или несколькими одинаковыми или различными заместителями, предпочтительно представляющими собой C-алкильную группу, атом галогена, линейную или разветвленную C-алкильную группу, C-алкиленовую ...

Подробнее
11-11-1982 дата публикации

Antineoplastic transition metal complexes and medicaments containing them

Номер: DE0003115919A1
Принадлежит:

Compounds of the general formula I [C6H5C(O)CHC(O)CH3]2+nMX2-n (I), in which M denotes zirconium or hafnium, X denotes fluorine, chlorine or bromine and n denotes the number 1 or 0, exhibit a potent cytostatic action in combination with very low toxicity and are suitable for the production of antineoplastic medicaments.

Подробнее
02-07-1997 дата публикации

Methods for the treatment of herpes virus infections

Номер: GB0009709360D0
Автор:
Принадлежит:

Подробнее
09-08-2012 дата публикации

Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators

Номер: AU2006285026B2
Принадлежит:

This invention provides: 1) a method of treating a subject suffering from, or predisposed to a kidney disease or disorder; 2) a method of treating a subject suffering from a wound, or reducing the incidence of, or mitigating the severity of a wound in a subject; 3) a method of treating a subject suffering from a burn, or reducing the incidence of, or mitigating the severity of a burn in a subject, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound; 4) a method of treating a subject suffering from a spinal cord injury, by administering to the subject a selective androgen receptor modulator (SARM) and/or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.

Подробнее
23-12-2004 дата публикации

PHARMACEUTICAL COMPOSITION AND METHOD FOR ALLEVIATING SIDE EFFECTS OF ESTROGEN REPLACEMENT THERAPY

Номер: CA0002529225A1
Принадлежит:

The present invention provides pharmaceutical compositions for alleviating pathological conditions in a post-menopausal woman, comprising lysine, proline, arginine, ascorbic acid, magnesium, green tea extract, N-acetyl- cysteine, selenium, copper, manganese and one pharmaceutical acceptable component selected from the group consisting of a carrier, a diluent, and an excipient, wherein the compositions contain 24-25 wt % lysine, 16-25 wt % ascorbic acid and 22-25 wt % green tea extract. A method of treatment using the pharmaceutical compositions are also disclosed.

Подробнее
02-06-2016 дата публикации

HAPTEN-ENHANCED CHEMOIMMUNOTHERAPY BY ULTRA-MINIMUM INCISION PERSONALIZED INTRATUMORAL CHEMOIMMUNOTHERAPY

Номер: CA0002968853A1
Автор: YU, BAOFA, YU BAOFA
Принадлежит:

Embodiments disclosed herein provide methods for treating neoplasm in a mammal, comprising intratumorally administering to the neoplasm an effective amount of a pharmaceutical composition comprising: a hapten; and a redox agent, whereby the neoplasm is treated.

Подробнее
18-05-2007 дата публикации

TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS

Номер: CA0002632697A1
Принадлежит:

Treatment of mitochondrial related conditions in mammals with antagonists or chelating agents of copper (II), preferably tetramines or penicillamines. These agents affect TGF-beta, Smad 4, collagen IV, cytochrome C oxidase and erectile dysfunction.

Подробнее
30-03-2004 дата публикации

THE REGULATION OF APPETITE, BODY WEIGHT AND ATHLETIC FUNCTION WITH MATERIALS DERIVED FROM CITRUS VARIETIES

Номер: CA0002248854C
Принадлежит: JONES, DENNIS, JONES DENNIS

Materials derived from Citrus plants can be administered orally to humans fo r the purpose of producing or maintaining weight loss as well as for improving the person's physical performance and increasing the person's lean muscle mass. The Citrus materials include those portions of the plant that are normally considered waste or inedible, such a s the leaves, peel, and immature, unripe fruit. The materials contain at least one of the alkaloids from the group consisting of synephrin e, hordenine, octopamine, tyramine and N-methyltyramine (1). Two species, Citrus aurantium and Citrus reticulata, are particularly useful . The materials can be administered in their natural form or as extracts, and can be administered in various ways including capsules and tablets. The Citrus materials may also be used as a tea. For weight loss and weight control, the materials can be administered concurrently with caloric restriction or in the absence of caloric restriction. The materials may also be administered ...

Подробнее
07-07-2005 дата публикации

COMPOSITION COMBINATIONS AND METHODS FOR TREATING, PREVENTING, REVERSING AND INHIBITING PAIN

Номер: WO2005060437A2
Автор: SALVEMINI, Daniela
Принадлежит:

The invention provides a combination of compositions for treating, preventing, reversing or inhibiting pain, wherein at least one composition comprises a nitration inhibitor. Further provided is a method wherein the nitration inhibitor is selected from the group consisting of a SO generating system inhibitor, SO scavenger, NOS inhibitor, NO generating system inhibitor, NO scavenger, peroxynitrite generating system inhibitor, peroxynitrite scavenger, and any combination thereof. Preferably, the nitration inhibitor is combined with a pain inhibitor. The pain inhibitor is still more preferably an opioid.

Подробнее
22-03-2007 дата публикации

Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators

Номер: US2007066568A1
Принадлежит:

This invention provides: 1) a method of treating a subject suffering from, or predisposed to a kidney disease or disorder; 2) a method of treating a subject suffering from a wound, or reducing the incidence of, or mitigating the severity of a wound in a subject; 3) a method of treating a subject suffering from a burn, or reducing the incidence of, or mitigating the severity of a burn in a subject, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound; 4) a method of treating a subject suffering from a spinal cord injury, by administering to the subject a selective androgen receptor modulator (SARM) and/or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.

Подробнее
17-09-2018 дата публикации

Номер: RU2016126429A3
Автор:
Принадлежит:

Подробнее
20-05-2015 дата публикации

СЕЛЕКТИВНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА

Номер: RU2013149821A
Принадлежит:

... 1. Способ лечения, снижения степени тяжести, снижения заболеваемости, задержки начала или ослабления патогенеза атрофии мышц у субъекта-человека с немелкоклеточным раком легких, включающий этап введения указанному субъекту соединения - селективного модулятора рецепторов андрогенов (SARM) формулы II:гдеХ является О;Z является акцептором водородной связи, NO, CN, COR, CONHR;Y является жирорастворимой группой, CF, CH, формилом, алкоксигруппой, H, F, I, Br, Cl, Sn(R);R является алкилом, арилом, фенилом, алкенилом, галоалкилом, галоалкенилом, галогеном или OH;иQ является алкилом, галогеном, N(R), CN, NHCOCH, NHCOCF, NHCOR, NHCONHR, NHCOOR, OCONHR, CONHR, NHCSCH, NHCSCF, NHCSR, NHSOCH, NHSOR, OR, COR, OCOR, OSOR, SOR или SR, ацетамидо-, трифторацетамидо-, алкиламином, простой эфирной группой, алкилом, N-сульфонилом, O-сульфонилом, алкилсульфонилом, карбонилом или кетоном.2. Способ по п.1, отличающийся тем, что указанное соединение характеризуется структурой формулы III:3. Способ по п.1, отличающийся ...

Подробнее
31-10-1956 дата публикации

Improvements in or relating to veterinary compositions

Номер: GB0000760056A
Автор:
Принадлежит:

Veterinary compositions contain organo-tin compounds of the kind disclosed in the parent Specification but in different amounts. In addition, several further examples are given, including compounds wherein the electro-negative groups are phenolates, benzene sulphonates, benzene arsonates. Other tin compounds are produced by condensing a dialkyl tin sulphide with 2 mols. of the mercaptide of an ester such as butyl acetate according to the probable equation or with 1 mol. of an unesterified mercapto acid according to the probable equation or, in the case of a dicarboxylic acid, or with 2 mols. of an alcohol according to the probable equation ALSO:A veterinary composition for the control of protozoan infections and/or in enhancing the meat-producting capacity, &c. of fowl and domesticated animals comprises from 0.002 per cent up to, but not including 0.05 per cent, or from more than 0.2 per cent and ...

Подробнее
19-07-2001 дата публикации

PHARMACEUTICAL COMPOSITION AND METHOD OF USING THE SAME

Номер: CA0002396368A1
Автор: PHILLIPS, MARK W.
Принадлежит:

A pharmaceutical composition is provided for systemically treating a living mammal or avian. The composition preferably comprises an alkyl-dimethyl-benzyl- ammonium chloride, an alkyl-dimethyl-ethylbenzyl-ammonium chloride, and an organotin compound in a vehicle suitable for systemically treating a living mammal or avian of viral, bacterial, fungal infections and diseases, including HIV in humans.

Подробнее
05-01-2016 дата публикации

TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS

Номер: CA0002632697C

Treatment of mitochondrial related conditions in mammals with antagonists or chelating agents of copper (II), preferably tetramines or penicillamines. These agents affect TGF-beta, Smad 4, collagen IV, cytochrome C oxidase and erectile dysfunction.

Подробнее
08-01-2019 дата публикации

TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS

Номер: CA0002883060C

Treatment of mitochondrial related conditions in mammals with antagonists or chelating agents of copper (II), preferably tetramines or penicillamines. These agents affect TGF-beta, Smad 4, collagen Iv, cytochrome C oxidase and erectile dysfunction.

Подробнее
29-06-2017 дата публикации

HAPTEN-ENHANCED CHEMOIMMUNOTHERAPY BY ULTRA-MINIMUM INCISION PERSONALIZED INTRATUMORAL CHEMOIMMUNOTHERAPY

Номер: SG11201704175WA
Автор: YU BAOFA, YU, Baofa
Принадлежит:

Подробнее
13-09-2018 дата публикации

MOTUPORAMINE DERIVATIVES AS ANTIMICROBIAL AGENTS AND ANTIBIOTIC ENHANCERS AGAINST RESISTANT GRAM-NEGATIVE BACTERIA

Номер: US20180258029A1
Принадлежит:

Motuporamine agents having antimicrobial activity and uses thereof.

Подробнее
30-12-2009 дата публикации

The regulation of body weight with materials derived from citrus varieties

Номер: EP0885008B1
Автор: Jones, Dennis
Принадлежит: Jones, Dennis

Подробнее
01-07-1959 дата публикации

Veterinary compositions containing organotin compounds

Номер: GB0000815818A
Автор:
Принадлежит:

The invention comprises stannonium compounds of formula [RmSn(Am)y]X4-m, wherein R is an aliphatic, aromatic or heterocyclic group which may be substituted, m is 2 or 3, Am is amine or heterocyclic base, y is 1 or 2 and X is halogen, or a residue of a carboxylic acid, an ester thereof, a mercaptoacid, an ester thereof, an arylsulphonic acid, a sulphonamide, a dithiocarbamate, an isodithiocarbamate or a xanthate, or an ORa or SRa group wherein Ra is a hydrocarbon group which may be substituted. They may be prepared by reacting an organotin compound of formula R2SnX2 or R3SnX with the amine or base. R may be an alkyl, alkenyl, alkaryl or aralkyl group having up to 22 carbon atoms in the open chain. Specified amines and bases include octyl amine, lauryl amine, stearyl amine, oleyl amine, cyclohexylamine, benzyl amine, aniline, p-phenylene diamine, dioctyl amine, dicetylamine, dilauryl amine, dodecylmethyl amine, dicyclohexyl amine, methyl aniline, piperidine, morpholine, piperazine, phenothiazine ...

Подробнее
19-03-2004 дата публикации

METHOD TO TREAT LAMINITIS AND REDUCE DIETARY INTAKE FOR HORSES

Номер: AU2003265809A1
Принадлежит:

Подробнее
14-07-2016 дата публикации

Stabilized stannous compositions

Номер: AU2014373625A1
Принадлежит:

The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti- calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.

Подробнее
15-11-2018 дата публикации

Oral care compositions

Номер: AU2017281239B2
Принадлежит: Griffith Hack

An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Подробнее
18-05-2007 дата публикации

TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS

Номер: CA0002883060A1
Принадлежит:

Treatment of mitochondrial related conditions in mammals with antagonists or chelating agents of copper (II), preferably tetramines or penicillamines. These agents affect TGF-beta, Smad 4, collagen Iv, cytochrome C oxidase and erectile dysfunction.

Подробнее
20-11-2018 дата публикации

Номер: KR0101920292B1
Автор:
Принадлежит:

Подробнее
11-10-2012 дата публикации

SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES

Номер: WO2012139093A3
Принадлежит:

This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC.

Подробнее
23-09-2004 дата публикации

METHODS AND COMPOSITIONS FOR BLOCKING THE CALCIUM CASCADE

Номер: WO2004080417A3
Автор: SCEUSA, Nicholas, A.
Принадлежит:

Methods and compositions are provided for blocking the calcium cascade. More particularly, compositions and methods are provided that inhibit histamine reactions triggered by the calcium cascade, and those other reactions causally connected to the cascade using the naturally occurring pH gradients in the body to deliver therapeutic doses of metal ions which block the calcium cascade, or by conventional means.

Подробнее
19-08-1997 дата публикации

Methods for the treatment of herpes virus infections

Номер: US0005658946A1
Автор: Majeti; Satyanarayana
Принадлежит: The Procter & Gamble Company

Disclosed are methods for treatment of herpes virus infections in a human or lower animal subject comprising administering to the subject stannous salt and one or more pharmaceutically acceptable carriers suitable for topical administration. The stannous salt may be one or more stannous carboxylates, a stannous halide selected from the groups consisting of stannous bromide, stannous iodide, and stannous chloride dihydrate, two or more stannous halides, or one or more stannous halides and one or more stannous carboxylates. Another therapeutic agent, such as an anesthetic, analgesic, or antibiotic, may also be administered. Also disclosed are compositions effective in treating herpes virus infections in a human or lower animal subject comprising stannous fluoride, one or more therapeutic agents, and one or more pharmaceutically acceptable carriers suitable for topical administration.

Подробнее
06-08-2014 дата публикации

COMPOSITIONS CONTAINING SPERMINE TOGETHER WITH CADAVERINE, PUTRESCINE AND/OR SPERMIDINE

Номер: EP2760442A1
Принадлежит:

Подробнее
24-07-2001 дата публикации

Pharmaceutical composition and method of using the same

Номер: AU0002636101A
Принадлежит:

Подробнее
23-10-2008 дата публикации

SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES

Номер: CA0002683767A1
Принадлежит:

This invention provides use of a SARM compound or a composition comprisin g the same in treating a variety of diseases or conditions in a subject, inc luding, inter-alia, a diabetes disease, and/or disorder such as cardiovascul ar disease, atherosclerosis, cerebrovascular conditions, diabetic nephropath y, diabetic neuropathy and diabetic retinopathy.

Подробнее
08-03-2007 дата публикации

TREATING RENAL DISEASE, BURNS, WOUNDS AND SPINAL CORD INJURY WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS

Номер: CA0002621189A1
Принадлежит:

This invention provides: 1) a method of treating a subject suffering from, or predisposed to a kidney disease or disorder; 2) a method of treating a subject suffering from a wound, or reducing the incidence of, or mitigating the severity of a wound in a subject; 3) a method of treating a subject suffering from a burn, or reducing the incidence of, or mitigating the severity of a burn in a subject, comprising the step of administering to said subject a selective androgen receptor modulator (SARM) compound; 4) a method of treating a subject suffering from a spinal cord injury, by administering to the subject a selective androgen receptor modulator (SARM) and/or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.

Подробнее
09-04-1998 дата публикации

THE REGULATION OF APPETITE, BODY WEIGHT AND ATHLETIC FUNCTION WITH MATERIALS DERIVED FROM CITRUS VARIETIES

Номер: CA0002248854A1
Принадлежит:

Materials derived from Citrus plants can be administered orally to humans for the purpose of producing or maintaining weight loss as well as for improving the person's physical performance and increasing the person's lean muscle mass. The Citrus materials include those portions of the plant that are normally considered waste or inedible, such as the leaves, peel, and immature, unripe fruit. The materials contain at least one of the alkaloids from the group consisting of synephrine, hordenine, octopamine, tyramine and Nmethyltyramine (1). Two species, Citrus aurantium and Citrus reticulata, are particularly useful. The materials can be administered in their natural form or as extracts, and can be administered in various ways including capsules and tablets. The Citrus materials may also be used as a tea. For weight loss and weight control, the materials can be administered concurrently with caloric restriction or in the absence of caloric restriction. The materials may also be administered ...

Подробнее
07-07-2005 дата публикации

COMPOSITION COMBINATIONS AND METHODS FOR TREATING, PREVENTING, REVERSING AND INHIBITING PAIN

Номер: WO2005060437A3
Автор: SALVEMINI, Daniela
Принадлежит:

The invention provides a combination of compositions for treating, preventing, reversing or inhibiting pain, wherein at least one composition comprises a nitration inhibitor. Further provided is a method wherein the nitration inhibitor is selected from the group consisting of a SO generating system inhibitor, SO scavenger, NOS inhibitor, NO generating system inhibitor, NO scavenger, peroxynitrite generating system inhibitor, peroxynitrite scavenger, and any combination thereof. Preferably, the nitration inhibitor is combined with a pain inhibitor. The pain inhibitor is still more preferably an opioid.

Подробнее
14-02-1989 дата публикации

Metal complexes having an antineoplastic action and medicaments containing these complexes

Номер: US0004804681A1
Принадлежит:

Complexes of the general formula I [R1 (CH2)m C(O)CR3 C(O)R2 ]2+n MX2-n (I) wherein M denotes tin, titanium, zirconium or hafnium, R1 denotes hydrogen or a phenyl radical, it being possible for the phenyl radical to be monosubstituted or polysubstituted by fluorine, chlorine, bromine, nitro, C1 -C4 -alkyl, C1 -C4 -alkoxy or trifluoromethyl, R2 denotes methyl or R1, with the exception of hydrogen, R3 denotes hydrogen or chlorine, X denotes fluorine, chlorine or bromine, but not fluorine if M denotes zirconium or hafnium, m denotes the number 1 or 0, or, if R1 denotes hydrogen, the number 1 and n denotes the number 0, or, if M denotes zirconium or hafnium, the number 1 or 0, exhibit a cytostatic activity which is comparable to that of cisplatin and are less toxic than cisplatin. They are suitable for the produduction of medicaments having an anti-neoplastic action.

Подробнее
08-12-2016 дата публикации

Oral composition

Номер: AU2015276158A1
Принадлежит: Spruson & Ferguson

The present invention relates to a composition comprising an antibacterial agent in an amount insufficient to provide antibacterial effect, a physiologically acceptable divalent metal ion in a very low concentration and a physiologically acceptable polymer for preventing and/or treating halitosis, bad breath, dry mouth or sore throat.

Подробнее
29-08-2019 дата публикации

Oral care compositions

Номер: AU2019200755B2
Принадлежит: Shelston IP Pty Ltd.

An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Подробнее
23-06-2005 дата публикации

EDIBLE COMPOSITIONS WHICH ARE ADAPTED FOR USE BY A COMPANION ANIMAL

Номер: CA0002547378A1
Принадлежит:

Disclosed herein are a variety of embodiments of compositions and methods which are each adapted for use by a companion animal. In one embodiment, an edible composition comprising an amount of a soluble mineral component is disclosed, wherein the soluble mineral component comprises one or more minerals selected from the group consisting of zinc, manganese, tin, copper, and mixtures thereof, wherein the amount is an effective amount for use as an oral medicament. In further embodiments, a phosphate component is included. The edible compositions are advantageously companion animal foods or supplements. Further disclosed are methods selected from treating oral cavity tartar, oral cavity plaque, periodontal disease, gingivitis, breath odor and combinations thereof comprising orally administering a described composition to a companion animal.

Подробнее
28-04-2005 дата публикации

TREATING BONE-RELATED DISORDERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS

Номер: CA0002535953A1
Принадлежит:

This invention provides method of treating, preventing, suppressing, inhibiting, or reducing the risk of developing a bone-related disorder, for example osteoporosis, osteopenia, increased bone resorption, bone fracture, bone frailty and/or loss of bone mineral density (BMD), by administrating a therapeutically effective amount of a selective androgen receptor modulator (SARM) and/or its analogue, derivative, isomer, metabolite pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof. The invention also provides methods of decreasing fat mass (FM) and increasing lean mass, comprising administering same.

Подробнее
15-09-2020 дата публикации

HIGH WATER ORAL CARE COMPOSITION COMPRISING ZINC AND TIN SALTS

Номер: CA0002996319C

An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Подробнее
14-07-2016 дата публикации

ORAL DELIVERY PRODUCT

Номер: CA0002918005A1
Принадлежит:

This invention provides a nutritional supplement composition which is a vitamin mint that can be taken without water or other liquid which is usually required for swallowing a tablet.

Подробнее
02-07-2015 дата публикации

STABILIZED STANNOUS COMPOSITIONS

Номер: CA0002932294A1
Принадлежит:

The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti- calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.

Подробнее
29-06-1943 дата публикации

Номер: US0002323218A1
Автор:
Принадлежит:

Подробнее
13-07-2017 дата публикации

Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

Номер: AU2015353539A1
Автор: YU BAOFA, Yu, Baofa
Принадлежит: Allens Patent & Trade Mark Attorneys

Embodiments disclosed herein provide methods for treating neoplasm in a mammal, comprising intratumorally administering to the neoplasm an effective amount of a pharmaceutical composition comprising: a hapten; and a redox agent, whereby the neoplasm is treated.

Подробнее
28-12-2017 дата публикации

ORAL CARE COMPOSITIONS

Номер: CA0002996319A1
Принадлежит:

An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Подробнее
05-04-2013 дата публикации

COMPOSITIONS CONTAINING OF THE SPERMINE AND PHARMACEUTICAL COMPOSITIONS THE CONTAINER

Номер: FR0002980709A1
Принадлежит: NUTRIALYS MEDICAL NUTRITION SA

La présente invention porte sur des nouvelles compositions comprenant un mélange de cadavérine, putrescine et spermidine à une concentration variant de 0,3 à 0,6 nmoles par gramme de composition, ladite composition comprenant également de la spermine à une concentration variant de 150 à 17000 nmoles par gramme de composition, et leurs utilisations dans le traitement chez un patient de pathologies liées à l'hyperprolifération cellulaire.

Подробнее
19-01-2012 дата публикации

Formulations for the treatment of urushiol-induced contact dermatitis

Номер: US20120015044A1
Принадлежит: Laszlos Solutions Inc

Disclosed herein are compositions comprising: a pharmaceutically acceptable oxidizing agent; a pharmaceutically acceptable base; and a pharmaceutically acceptable solvent or mixture of solvents. Also disclosed are methods of treating urushiol-induced contact dermatitis in a patient, the method comprising: identifying a patient in need thereof; and administering to the patient a composition as described herein. Further disclosed herein are devices for the treatment of urushiol-induced contact dermatitis, the device comprising: an absorbent material, contained therein a composition as described herein; and means for attaching the device to the skin of a patient in need thereof.

Подробнее
29-03-2012 дата публикации

Medium chain peroxycarboxylic acid compositions

Номер: US20120077877A1
Принадлежит: ECOLAB USA INC

The present invention relates to compositions including medium chain peroxycarboxylic acid, methods for making these compositions, and methods for reducing the population of a microorganism. The compositions can include advantageously high levels of the medium chain peroxycarboxylic acid, can be readily made, and/or can exhibit reduced odor.

Подробнее
10-05-2012 дата публикации

Combination/association of adapalene and benzoyl peroxide for treating acne lesions

Номер: US20120115947A1
Принадлежит: Galderma Research and Development SNC

Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).

Подробнее
02-08-2012 дата публикации

Treatment of acne by conditioned media

Номер: US20120195969A1
Принадлежит: AIDAN RES AND CONSULTING LLC

Disclosed are methods and compositions for treatment of acne or acneform conditions, particularly but not limited to, acne vulgaris with products generated from culture of stem or progenitor cells. Specifically, compositions of matter are disclosed which are useful for the treatment of acne and acne associated disease states, in particular acne vulgaris, by topical administration of products derived from stem cells or progenitor cells.

Подробнее
04-10-2012 дата публикации

Combination composition comprising benzoyl peroxide and adapalene

Номер: US20120252897A1
Принадлежит: Glenmark Generics LTD

An aqueous gel composition of the present invention comprising about 0.1 to 0.3 wt % adapalene and about 2.5 to 5.0 wt % benzoyl peroxide, as active ingredients, wherein both the active ingredients are stabilized in hydrophilic gelling matrix of pH dependent gelling agent comprising crosslinked, acrylic acid-based polymer(s).

Подробнее
10-01-2013 дата публикации

Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent

Номер: US20130012460A1
Автор: Gordon J. Dow, Yunik Chang
Принадлежит: Dow Pharmaceutical Sciences Inc

An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following, application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.

Подробнее
21-03-2013 дата публикации

PERACID AND 2-HYDROXY ORGANIC ACID COMPOSITIONS AND METHODS FOR SANITATION AND DISEASE PREVENTION

Номер: US20130072563A1
Автор: Ho Kai Lai Grace
Принадлежит: Fresh Express Incorporated

Methods and compositions for treating living surfaces to control microorganisms are provided. The method treats produce by contacting a living surface with an aqueous solution comprising i) an organic peracid of the formula RC(O)OOH wherein R is methyl, ethyl, n-propyl, or s-propyl; ii) a 2-hydroxy organic acid selected from tartaric acid, citric acid, malic acid, mandelic acid, and lactic acid; and iii) water. 1. A method of treating skin or mucosa comprising contacting the surface with an aqueous composition which comprises:i) an organic peracid of the formula RC(O)OOH wherein R is methyl, ethyl, n-propyl, or s-propyl;ii) a 2-hydroxy organic acid selected from tartaric acid, citric acid, malic acid, mandelic acid, and lactic acid; and, optionally, a surfactant;wherein the aqueous composition has a pH from 2.5 to 7.8, inclusive and the concentration of peracid is from 40 to 250 ppm (w/w) inclusive, and the concentration of the 2-hydroxy organic acid is from 0.1 to 1% (w/w), inclusive.2. The method of claim 1 , wherein the composition also comprises an anionic surfactant.3. The method of claim 1 , wherein the peracid is peroxyacetic acid and the 2-hydroxy organic acid is L-(+)-lactic acid.4. The method of claim 3 , wherein the concentration of the peroxyacetic acid in the composition is from 50 to 100 ppm (w/w) claim 3 , the concentration of the lactic acid in the composition is from 0.1% to 0.6% (w/w).5. The method of claim 3 , wherein concentration of peroxyacetic acid in the composition is from 60 to 80 ppm (w/w) claim 3 , the concentration of lactic acid in the composition is from 0.1% to 0.4% (w/w).6. The method of claim 3 , wherein the pH is between 2.5 and 4.5.7. The method of claim 1 , wherein the pH is from 2.8 to 3.2.8. The method of claim 1 , wherein the pH is about 3.0.9. The method of claim 1 , wherein the composition is at a temperature of 35° F. to 45° F.10. The method of claim 1 , wherein the composition is substantially free of nonionic surfactants ...

Подробнее
04-04-2013 дата публикации

Baclofen and acamprosate based therapy of neurological disorders

Номер: US20130085122A1
Принадлежит: Pharnext SA

The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.

Подробнее
18-04-2013 дата публикации

SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS

Номер: US20130096127A1
Принадлежит: NOVARTIS AG

The present invention provides a compound of formula I′; 3. The compound of wherein:{'sup': '1', 'sub': '1-7', 'Ris H or Calkyl;'}{'sup': 2', 'a', 'b', 'a', 'b, 'sub': 1-7', '3-7', '1-7', '1-7', '6-20', '1-7, 'Rfor each occurrence, is independently Calkyl, halo, Ccycloalkyl, hydroxy, Calkoxy, haloCalkyl, —NRR, Caryl, heteroaryl or heterocyclyl; wherein Rand Rfor each occurrence are independently H or Calkyl;'}{'sup': 3', '1', '1, 'Ris A-C(O)X;'}{'sup': '5', 'Ris H; and'}{'sup': 1', 'a', 'b, 'sub': '1-7', 'X and Xare independently OH, —O—Calkyl or NRR;'}{'sup': '1', 'Bis —C(O)NH— or —NHC(O)—;'}{'sup': '1', 'sub': 1-7', '3-7', '1-7', '3-7, 'Ais a linear or branched Calkylene; which is optionally substituted with one or more substituents independently selected from the group consisting of halo, Ccycloalkyl, Calkoxy, hydroxy and O-acetate; in which two geminal alkyl can optionally combine to form a Ccycloalkyl; or'}and wherein each heteroaryl is a monocyclic or bicyclic aromatic ring comprising 5-10 ring atoms selected from carbon atoms and 1 to 5 heteroatoms, and', 'each heterocyclyl is a monocyclic saturated or partially saturated but non-aromatic moiety comprising 4-7 ring atoms selected from carbon atoms and 1-5 heteroatoms, wherein each heteroatom of a heteroaryl or a heterocyclyl is independently selected from O, N and S, or a pharmaceutically acceptable salt thereof., 'n is 0, 1, 2, 3, 4 or 5;'}6. The compound of wherein Ais an optionally substituted linear or branched Calkylene claim 1 , or a pharmaceutically acceptable salt thereof.7. The compounds of wherein Ais CHCH claim 1 , or a pharmaceutically acceptable salt thereof.810-. (canceled)11. The compound of wherein Ris H claim 1 , Ris independently halo claim 1 , Calkoxy claim 1 , hydroxy claim 1 , Calkyl or halo-Calkyl claim 1 , n is 0 claim 1 , 1 or 2 and X and Xare independently OH or —O—Calkyl claim 1 , or a pharmaceutically acceptable salt thereof.12. The compounds of wherein n is 1 or 2; Ris meta-chloro ...

Подробнее
18-04-2013 дата публикации

Low toxicity topical active agent delivery system

Номер: US20130096203A1
Автор: John E. Kulesza
Принадлежит: Young Pharmaceuticals Inc

An active agent delivery composition is provided that allows topical delivery of active agents including vitamin A and its derivatives. A polyhalogenic vehicle such as methoxyonafluorobutane or ethoxyonafluorobutane serves as a coupler for an active agent and a silicone carrier so as to allow solubilization of active agents not normally miscible in silicones and providing a moisture maintaining composition.

Подробнее
25-04-2013 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA, 15-OHEPA, AND/OR 15-HETRE AND METHODS OF USE THEREOF

Номер: US20130102575A1
Принадлежит: DIGNITY SCIENCES LIMITED

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the treatment of disease and/or disorders such as acne or atopic dermatitis. 111-. (canceled)12. A method for treating or preventing acne in a subject in need thereof , the method comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of DGLA , 15-OHEPA , or 15-HETrE.13. The method of claim 12 , wherein the pharmaceutical composition comprises about 0.1 wt. % to about 20 wt. % of DGLA claim 12 , 15-OHEPA claim 12 , or 15-HETrE.14. The method of claim 13 , wherein the pharmaceutical composition comprises about 1.65 wt. % steareth-2 claim 13 , about 1.35 wt. % steareth-21 claim 13 , about 0.5 wt. % cetyl alcohol claim 13 , about 0.2 wt. % ascorbyl palmitate claim 13 , about 0.15 wt. % a-tocopherol claim 13 , about 2.0 wt. % medium-chain triglycerides (e.g. claim 13 , Crodamol GTCC) claim 13 , about 2.0 wt. % myristyl myristate claim 13 , about 4.0 wt. % isopropryl palmitate claim 13 , about 1.0 wt. % glycerin claim 13 , about 1.0 wt. % phenoxyethanol claim 13 , about 0.1 wt. % ascorbic acid claim 13 , about 0.8 wt. % carbomer claim 13 , about 0.4 wt. % xanthan gum claim 13 , about 0.5 wt. % liquid soy lecithin claim 13 , and about 0.05 wt. % Mild Care 345 fragrance.15. The method of claim 13 , wherein the pharmaceutical composition comprising 15-OHEPA further includes a therapeutically effective amount of benzoyl peroxide.16. The method of claim 15 , wherein the pharmaceutical composition comprises about 1.25% to about 10 wt. % of benzoyl peroxide.17. The method of claim 13 , wherein the pharmaceutical composition comprising 15-HETrE further includes a therapeutically effective amount of adapalene.18. The method of claim 17 , wherein the pharmaceutical composition comprises about 0. ...

Подробнее
02-05-2013 дата публикации

TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS

Номер: US20130108709A1
Принадлежит:

Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression. 1. A method for improving age-related physiological deficits and increasing longevity in a mammal comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable copper (II) antagonist and a pharmaceutically acceptable carrier.2. The method of wherein said copper antagonist is a linear or branched tetramine capable of binding copper (II).3. The method of wherein said linear or branched tetramine is a copper (II) chelator.4. The method of wherein said linear or branched tetramine is selected from the group consisting of 2 claim 3 ,3 claim 3 ,2 tetramine claim 3 , 2 claim 3 ,2 claim 3 ,2 tetramine claim 3 , and 3 claim 3 ,3 claim 3 ,3 tetramine.5. The method of wherein said copper (II) antagonist is triethylenetetramine.6. The method of wherein said copper (II) antagonist is a triethylenetetramine salt.7. The method of wherein said triethylenetetramine salt is a succinate salt.8. The method of wherein said triethylenetetramine succinate salt is triethylenetetramine disuccinate.9. The method of wherein said composition is a tablet or capsule for oral administration.10. The method of wherein said composition is a long-acting tablet or capsule for oral administration.11. The method of wherein said copper antagonist is selected from the group consisting penicillamine claim 1 , N- ...

Подробнее
23-05-2013 дата публикации

USE OF A DERMATOLOGICAL COMPOSITION COMPRISING A COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE WHICH IS INTENDED FOR THE TREATMENT OF ACNE IN NON-CAUCASIAN POPULATION WITH DECREASE OF POST-INFLAMMATORY HYPERPIGMENTATION

Номер: US20130131177A1
Принадлежит: GALDERMA RESEARCH & DEVELOPMENT

A dermatological composition including a combination of Adapalene and benzoyl peroxide is described. The composition is intended for the treatment of acne in the non-Caucasian population with decreased post-inflammatory hyperpigmentation, keloid scarring and acne hyperpigmented macules and cystic lesions. 1. A method of preparing a medicament for treating acne in a non-Caucasian subject , the method comprising preparing the medicament by combining effective amounts of Adapalene and benzoyl peroxide.2. The method as defined by claim 1 , wherein administration of the medicament decreases at least one sign or symptom of pathologies or disorders selected from the group consisting of post-inflammatory hyperpigmentation claim 1 , keloid scarring claim 1 , acne hyperpigmented macules and cystic lesions.3. The method as defined by claim 1 , wherein the medicament is in a form suitable for topical application.4. The method as defined by claim 1 , wherein the benzoyl peroxide is present at a concentration of from 1% to 10% by weight with respect to the total weight of the medicament.5. The method as defined by claim 1 , wherein the Adapalene is present at a concentration of from 0.001% to 20% by weight claim 1 , with respect to the total weight of the medicament.6. The method as defined by claim 1 , wherein the medicament is in the form of a gel claim 1 , emulsion claim 1 , or lotion.7. The method as defined by claim 1 , wherein the medicament is in the form of a composition comprising an aqueous gel having the following composition claim 1 , as percentage by weight with respect to the total weight:2.5% of BPO;0.1% of adapalene;0.10% of disodium EDTA;4.00% of glycerol;4.00% of propylene glycol;and also, optionally:0.05% of sodium docusate;0.20% of poloxamer 124; and4.00% of sodium acryloyldimethyltaurate copolymer and isohexadecane and polysorbate 80.8. The method as defined by claim 4 , wherein the benzoyl peroxide is present at a concentration of from 2% to 5% by weight.9. ...

Подробнее
27-06-2013 дата публикации

METHODS AND FORMULATIONS FOR TREATING INEFFECTIVE OR DECREASED ESOPHAGAL MOTILITY

Номер: US20130165508A1
Автор: Stover Robert C.
Принадлежит:

Disclosed embodiments describe pharmaceutical compositions and methods for treating ineffective esophageal motility in which bethanechol and pharmaceutically acceptable absorption enhancers including bile acids and mixtures thereof are topically introduced to the esophagus. Therapeutically effective amounts of bethanechol are delivered while reducing or eliminating parasympathetic nervous system side effects normally associated with systemic bethanechol delivery. 1. A method for effecting the gastrointestinal absorption of a pharmaceutical treatment that has an active ingredient with a stable ionic charge at physiological pH comprising:combining the active ingredient with a complimentary counter-ionic molecule, the counter-ionic molecule comprising a charged moiety for complimenting the charge of the active ingredient and a hydrophobic moiety; andformulating the treatment for application to the gastrointestinal tract.2. The method of claim 1 , wherein:the active ingredient is bethanechol.3. The method of claim 2 , wherein:the counter-ionic molecule comprises one or more bile acids.4. The method of claim 3 , wherein:the molar ratio of counter-ionic molecule to active ingredient is at least 10:1.5. The method of claim 4 , wherein:the bile acids comprise taurocholic acid, glycocholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycochenodeoxycholic acid, and glycodeoxycholic acid.6. The method of claim 5 , wherein:the bile acids are present in approximately the following amounts: taurocholic acid from about 30 to about 40 wt. percent; glocoycholic acid from about 20 to about 30 wt. percent; taurochenodeoxycholic acid from about 1 to about 5 wt. percent; taurodeoxycholic acid from about 5 to about 10 wt. percent; glycochenodeoxycholic acid from about 1 to about 5 wt. percent; and glycodeoxycholic acid from about 1 to about 10 wt. percent.7. A topical pharmaceutical composition for the treatment of ineffective esophageal motility claim 5 , comprising:from ...

Подробнее
08-08-2013 дата публикации

Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease

Номер: US20130202712A1
Принадлежит: Vindico Nanobiotechnology Inc

The present invention relates to compositions and methods for the treatment of immuno-inflammatory conditions comprising the administration of a polyphenolic phytoalexin compartmentalized in a biocompatible and/or biodegradable polymeric carrier, and to the use of biocompatible and/or biodegradable polymeric carriers comprising resveratrol and block copolymers and these compositions with an additional compartmentalized pharmaceutically active agent.

Подробнее
29-08-2013 дата публикации

NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER

Номер: US20130224123A1
Принадлежит: ALKERMES PHARMA IRELAND LIMITED

The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions. 153.-. (canceled)54. A method of treating a subject in need comprising administering or applying a nanoparticulate active agent composition comprising:(a) at least one active agent having an effective average particle size of less than about 2000 nm; and(b) lysozyme adsorbed on or associated with the surface of the active agent.55. The method of claim 54 , wherein the at least one active agent is selected from the group consisting of a drug claim 54 , vitamin claim 54 , herb claim 54 , cosmetic agent claim 54 , coloring agent claim 54 , flavor agent claim 54 , fragrance agent claim 54 , sunscreen claim 54 , moisturizer claim 54 , deodorant claim 54 , hair conditioner agent claim 54 , hair dye claim 54 , hair spray agent claim 54 , hair cosmetic agent claim 54 , hair cleanser agent claim 54 , and depilatory agent.56. The method of claim 54 , wherein the at least one active agent is selected from the group consisting of proteins claim 54 , peptides claim 54 , nutraceuticals claim 54 , carotenoids claim 54 , anti-obesity agents claim 54 , corticosteroids claim 54 , elastase inhibitors claim 54 , analgesics claim 54 , anti-fungals claim 54 , oncology therapies claim 54 , anti-emetics claim 54 , analgesics claim 54 , cardiovascular agents claim 54 , anti-inflammatory agents claim 54 , anthelmintics claim 54 , anti-arrhythmic agents claim 54 , antibiotics claim 54 , anticoagulants claim 54 , antidepressants claim 54 , antidiabetic agents claim 54 , antiepileptics claim 54 , antihistamines claim 54 , antihypertensive agents claim 54 , antimuscarinic agents claim 54 , antimycobacterial agents claim 54 , antineoplastic agents claim 54 ...

Подробнее
29-08-2013 дата публикации

Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain

Номер: US20130224151A1
Принадлежит:

The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors alone or in combination for the treatment or prevention of abdominal, visceral or pelvic pain. Also described herein are pharmaceutical compositions comprising a FAAH inhibitor, alone or in combination with an additional therapeutic agent for the treatment of abdominal, visceral or pelvic pain. 1169-. (canceled)170. A method of treating or preventing abdominal , visceral or pelvic pain in a patient in need thereof , comprising administering a therapeutically or prophylactically effective amount of a FAAH inhibitor to said patient.171. The method according to claim 170 , wherein the pain is selected from:(a) gastrointestinal pain: stomach pain, rectal pain, bowel pain, intestinal pain, intestinal cramps, pain and/or discomfort associated with irritable bowel syndrome (IBS), pain and/or discomfort associated with inflammatory bowel disease (IBD); pain and/or discomfort associated with functional dyspepsia, pain and/or discomfort associated with functional abdominal pain, pain and/or discomfort associated with ulcerative colitis, Crohn's disease or celiac disease; chest pain associated with gastro-esophageal reflux disease;(b) pancreas pain, liver pain; cardiac pain;(c) urological, renal or gynecological pain: kidney pain, ureter pain, bladder pain, prostate pain, gynecological pain, ovarian pain, uterine pain, labor pain, vulvar pain, vaginal pain, dysmenorrhea, dyspareunia, endometriosis, menstrual cramps, post-menopausal pelvic pain, pain and/or discomfort associated with vulvodynia, pain and/or discomfort associated with interstitial cystitis or painful bladder syndrome, pain and/or discomfort associated with prostatitis, pain associated with inflammatory pelvic disease.172. The method according to claim 170 , wherein the pain is abdominal claim 170 , visceral or pelvic pain caused by cancer claim 170 , by bacterial infections claim 170 , viral infections claim 170 , ...

Подробнее
29-08-2013 дата публикации

Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors

Номер: US20130225560A1
Автор: Hilt Dana, Koenig Gerhard
Принадлежит: EnVivo Pharmaceuticals, Inc.

A method for improving cognition comprising administering to a patient certain alpha-7 receptor agonists and an acetylcholinesterase inhibitor is described together with related compositions. 1. A method for improving cognition comprising administering to a patient a compound selected from the group consisting of: (S)-1-(2-fluorophenyl)ethyl (S)-quinuclidin-3-ylcarbamate , N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide (TC-5619) , (S)—N-(quinuclidin-3-yl)-1H-indazole-3-carboxamide , and (R)-3-(6-(1H-indol-5-yl)pyridazin-3-yloxy)quinuclidine or a pharmaceutically acceptable salt thereof , and an acetylcholinesterase inhibitor.2. The method of wherein the patient has been diagnosed with Alzheimer's disease or pre-Alzheimer's disease.3. The method of wherein the patient has been diagnosed with mild to moderate Alzheimer's disease.4. The method of wherein the patient has been diagnosed with moderate to severe Alzheimer's disease.5. The method of claim 1 , wherein the acetylcholinesterase inhibitor is selected from tacrine claim 1 , donepezil claim 1 , rivastigmine and galantamine.6. The method of wherein the acetylcholinesterase inhibitor is selected from donepezil claim 5 , rivastigmine and galantamine.7. The method of wherein the acetylcholinesterase inhibitor is selected from donepezil and rivastigmine.8. The method of claim 1 , wherein the patient has been administered an acetylcholinesterase inhibitor for a period of time prior to being administered a compound selected from the group consisting of: (S)-1-(2-fluorophenyl)ethyl (S)-quinuclidin-3-ylcarbamate claim 1 , (2S claim 1 , 3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide claim 1 , (S)—N-(quinuclidin-3-yl)-1H-indazole-3-carboxamide claim 1 , and (R)-3-(6-(1H-indol-5-yl)pyridazin-3-yloxy)quinuclidine or a pharmaceutically acceptable salt thereof.9. The method of wherein the prior administration has been for at least one month.10. The method ...

Подробнее
05-09-2013 дата публикации

Cell Permeable Inhibitors of Anaphase Promoting Complex

Номер: US20130230458A1
Автор: King Randall, ZENG Xing

The invention provides compositions and methods for treating cell cycle disorders. Compositions of the invention include proTAME, a prodrug analog of TAME, and, optionally, one or more therapeutic agents. 1. A composition comprising a prodrug of tosyl-L-arginine methylester (TAME) , wherein said compound diffuses across the plasma membrane of a cell.2. The composition of claim 1 , comprising a TAME derivative in which a guanidine is linked to a protecting group.3. The composition of claim 1 , wherein said prodrug comprises a TAME derivative in which a guanidine group is protected by a carbamate group.4. The composition of claim 1 , wherein said prodrug comprises an esterase-activatable N claim 1 ,N′-bis(acyloxymethyl carbamate) derivative of TAME.5. The composition of claim 1 , wherein said prodrug is characterized as having a eukaryotic cell permeability level at least 20% greater than that of TAME.7. A pharmaceutical composition comprising the compound of .8. The composition of claim 1 , wherein said cell is eukaryotic claim 1 , mammalian claim 1 , or human.9. The composition of claim 1 , wherein said compound inhibits an activity of an anaphase promoting complex (APC).10. The composition of claim 9 , wherein said compound contacts a component of a tetratricopeptide repeats (TPR) subcomplex of an APC.11. The composition of claim 10 , wherein said component of a TPR subcomplex is APC3/Cdc27 claim 10 , APC6 claim 10 , APC7 claim 10 , or APC8.12. The composition of claim 1 , wherein said compound induces a cell cycle checkpoint.13. The compound of claim 12 , wherein said cell cycle checkpoint is the spindle assembly checkpoint (SAC).14. A formulation comprising an amount of a prodrug of tosyl-L-arginine methylester (TAME) that is sufficient to inhibit the degradation of a substrate of an anaphase-promoting complex/cyclosome (APC) for arresting the mitotic cycle of a cell.15. The formulation of claim 9 , further comprising a pharmaceutical carrier.16. The formulation ...

Подробнее
12-09-2013 дата публикации

TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT

Номер: US20130236549A1
Автор: Chang Yunik, Dow Gordon J.
Принадлежит: Dow Pharmaceutical Sciences, Inc.

An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. 1. A method for treating acne comprising topically applying an effective amount of an aqueous formulation comprising benzoyl peroxide in a concentration less than 5.0% and at least 1.0% w/w and clindamycin in a concentration between 0.5% and 5.0% once daily to acne affected skin of a patient in need thereof , wherein the efficacy of the once daily application in terms of reduction of acne inflammatory and non-inflammatory lesions is similar to that obtained by twice daily application of a topical gel composition containing 5.0% benzoyl peroxide , 1% clindamycin , dioctyl sodium sulfosuccinate , and water.2. The method of wherein the concentration of benzoyl peroxide is between 2.0% and 4.0% w/w.3. The method of wherein the concentration of benzoyl peroxide is between 2.5% and 3.5% w/w.4. The method of wherein the concentration of benzoyl peroxide is 2.5%.5. The method of wherein the concentration of clindamycin is between 1.0% and 2.5%.6. The method of wherein the concentration of clindamycin is 1.0%.7. The method of wherein the 1% clindamycin is provided as 1.2% clindamycin phosphate.8. The method of ...

Подробнее
26-09-2013 дата публикации

Combinations of adapalene and benzoyl peroxide for treating acne lesions

Номер: US20130253062A1
Принадлежит: Galderma Research and Development SNC

Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.

Подробнее
24-10-2013 дата публикации

Foamable suspension gel

Номер: US20130280309A1
Принадлежит: STIEFEL RESEARCH AUSTRALIA PTY LTD

The present subject matter provides foamable suspension gels that foam after release from a container. The foamable suspension gels contain at least one pharmaceutically active agent that is sparingly soluble to insoluble in water, a second pharmaceutically active agent, and optionally a third active agent.

Подробнее
28-11-2013 дата публикации

DERMATOLOGICAL FOAMS OBTAINED FROM A GEL OR SUSPENSION CONTAINING A COMBINATION OF ADAPALENE AND BENZOYL PEROXIDE

Номер: US20130317108A1
Автор: At Emmanuelle
Принадлежит: GALDERMA RESEARCH & DEVELOPMENT

Intermediate compositions, and in particular gels and suspensions for foam compositions, are described that include adapalene and benzoyl peroxide in combination. Also described; is the dermatological use of such compositions. 1. A composition comprising a combination of adapalene and benzoyl peroxide wherein the composition is in the form of a foam and is obtained from an intermediate composition in the form of a gel or a suspension.2. The composition as defined by claim 1 , wherein the intermediate composition has a viscosity of greater than 8 claim 1 ,000 cps.3. The composition as defined by claim 1 , wherein the composition has a viscosity of between 8000 8 claim 1 ,000 cps and 32 000 32 claim 1 ,000 cps.4. The composition as defined by claim 1 , wherein the composition comprises:between 60% and 98% by weight, relative to the total weight of the composition, of a gel or suspension, andbetween 2% and 40% by weight, relative to the total weight of the composition, of at least one propellant gas.5. An intermediate composition in gel form claim 1 , the intermediate composition comprising in a physiologically acceptable medium:adapalene and benzoyl peroxide,water,at least one gelling agent and/or pH-independent gelling agent,at least one surfactant,at least one wetting agent,optionally, a chelating agent,optionally, at least one humectant and/or emollient,optionally, one or more additives.6. An intermediate composition in suspension form claim 1 , the intermediate composition comprising in a physiologically acceptable medium:adapalene and benzoyl peroxide,water,at least one gelling agent and/or pH-independent gelling agent,optionally, one or more suspension agents,at least one surfactant,at least one wetting agent,optionally, a chelating agent,optionally, at least one humectant and/or emollient,optionally, one or more additives.7. The intermediate composition as defined by claim 5 , wherein the composition comprises claim 5 , as a weight percentage relative to the ...

Подробнее
05-12-2013 дата публикации

CLEANSING AND ANTI-ACNE COMPOSITION

Номер: US20130323228A1
Автор: Norman Greg
Принадлежит:

Disclosed is a cleansing composition and methods for its use capable of treating acne comprising an anti-acne agent comprising benzoyl peroxide, a combination of cleansing agents comprising disodium laureth sulfosuccinate and sodium C14-16 olefin sulfonate, and a combination of skin active ingredients comprising fruit extract, niacinamide, extract, fruit extract, and extract/extract ferment filtrate. 1. A cleansing composition capable of treating acne comprising:(a) an anti-acne agent comprising benzoyl peroxide;(b) a combination of cleansing agents comprising disodium laureth sulfosuccinate and sodium C14-16 olefin sulfonate; and{'i': Cucurbita pepo', 'epilobium angustifolium', 'Silybum marianum', 'Lactobacillus/ganoderma lucidum', 'Lentinus edodes, '(c) a combination of skin active ingredients comprising fruit extract, niacinamide, extract, fruit extract, and extract/extract ferment filtrate.'}2. The cleansing composition of claim 1 , comprising 70 to 80% w/w of water and:(a) 3 to 7% w/w of benzoyl peroxide;(b) 10 to 15% w/w of the combination of the cleansing agents; and(c) 0.01 to 2% w/w of the combination of the skin active ingredients.3. The cleansing composition of claim 2 , further comprising: glycerin; acrylates copolymer; citric acid; sodium hydroxide; sodium cocoyl apple amino acids; carbomer; xanthan gum; glyceryl stearate; stearic acid; PEG-100 stearate; methyldihydrojasmonate; propanediol; sodium citrate; and cetyl alcohol.4. A method of cleansing skin comprising topically applying the compositions of to skin claim 1 , followed by rinsing the skin with water.5. The method of claim 4 , wherein rinsing is performed within 5 claim 4 , 4 claim 4 , 3 claim 4 , 2 claim 4 , or 1 minute(s) after topical application of any one of the compositions to skin.6. The method of claim 5 , wherein sebum is removed from skin.7. The method of claim 6 , wherein the skin comprises acne.8. A method of treating acne comprising topically applying the composition of to skin ...

Подробнее
12-12-2013 дата публикации

Wound Care Products with Peracid Compositions

Номер: US20130330397A1
Принадлежит: CHD BIOSCIENCE, INC.

Methods have been developed for incorporation of a peracid compound into or on wound application matrices, such as bandages or dressings, and other matrices which will favorably impact wound healing and help eliminate microbial infection. The peracid compound comprises a base compound that is metabolically pertinent to wound healing, the oxidized form of the base compound (a peracid), and an appropriate oxidizer, such as hydrogen peroxide. In addition, other excipients with wound healing potential, such as esters of the base compound, may be added to the peracid compound. The combination peracid-wound application matrices can be used to disinfect and heal various wound types with designed time release of the peracid compound. 1. A wound treating matrix comprising at least one layer which is non-aqueous that comprises an antimicrobial composition comprising a carboxylic acid , the peracid of said carboxylic acid , and an oxidizer in a non-aqueous medium.2. The wound treating matrix according to claim 1 , wherein the non-aqueous layer is biodegradable.3. The wound treating matrix according to claim 1 , wherein the non-aqueous layer is dissolvable.4. The wound treating matrix according to claim 1 , further comprises:an aqueous layer;wherein the aqueous layer is separated from the non-aqueous layer prior to use;wherein in use, the non-aqueous layer is exposed to the aqueous layer, and the antimicrobial composition migrates into the aqueous layer.5. The wound treating matrix according to claim 4 , further comprising a removable fluid-resistant barrier layer for initially separating the non-aqueous layer from the aqueous layer claim 4 , wherein in use claim 4 , the barrier is removed to allow contact between the non-aqueous layer and the aqueous layer.6. The wound treating matrix according to claim 1 , wherein the antimicrobial composition further comprises an ester of the carboxylic acid.7. The wound treating matrix according to claim 1 , wherein the antimicrobial ...

Подробнее
19-12-2013 дата публикации

DERMATOLOGICAL FOAMS OBTAINED FROM A GEL OR SUSPENSION CONTAINING BENZOYL PEROXIDE

Номер: US20130338235A1
Автор: At Emmanuelle
Принадлежит: GALDERMA RESEARCH & DEVELOPMENT

Intermediate compositions, and in particular gels and suspensions for preparing foam compositions, are described. The compositions can include benzoyl peroxide. Also described, is the dermatological use of such compositions. 1. A composition comprising benzoyl peroxide , wherein the composition is in the form of a foam and is obtained from an intermediate composition in the form of a gel or a suspension.2. The composition as defined by claim 1 , wherein the composition has a viscosity of greater than 8 claim 1 ,000 cps after preparation at room temperature from an intermediate composition in gel form.3. The composition as defined by claim 1 , wherein the composition has a viscosity of between 8 claim 1 ,000 cps and 32 claim 1 ,000 cps after preparation at room temperature from an intermediate composition in suspension form.4. The composition as defined by claim 1 , wherein the composition comprises:between 60% and 98% by weight relative to the total weight of the composition, of a gel or suspension, andbetween 2% and 40% by weight relative to the total weight of the composition, of at least one propellant gas.5. An intermediate composition in gel form claim 1 , wherein the intermediate composition comprises in a physiologically acceptable medium:benzoyl peroxide,water,at least one gelling agent and/or pH-independent gelling agent,at least one surfactant,at least one wetting agent,optionally, a chelating agent,optionally, at least one humectant and/or emollient, andoptionally, one or more additives.6. An intermediate composition in suspension form claim 1 , wherein the composition comprises claim 1 , in a physiologically acceptable medium:benzoyl peroxide,water,at least one gelling agent and/or pH-independent gelling agent,optionally, one or more suspension agents,at least one surfactant,at least one wetting agent,optionally, a chelating agent,optionally, at least one humectant and/or emollient, andoptionally, one or more additives.7. The intermediate composition as ...

Подробнее
09-01-2014 дата публикации

DERMATOLOGICAL COMPOSITIONS COMPRISING RETINOIDS, DISPERSED BENZOYL PEROXIDE AND CARRAGEENANS

Номер: US20140010884A1
Принадлежит: GALDERMA RESEARCH & DEVELOPMENT

Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris. 1. A topically applicable , chemically , physically and rheologically stable dermatological composition suited for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization , comprising thus effective amounts of at least one retinoid , dispersed benzoyl peroxide and at least one carrageenan gelling agent , formulated into a topically applicable , physiologically acceptable medium therefore.2. The dermatological composition as defined by claim 1 , said at least one retinoid comprising a naphthoic acid compound.3. The dermatological composition as defined by claim 1 , comprising from 0.1 to 20% by weight with respect to the total weight of the composition claim 1 , of carrageenan.4. The dermatological composition as defined by claim 1 , further comprising at least one additional gelling agent.5. The dermatological composition as defined by claim 4 , said at least one additional gelling agent comprising a semisynthetic cellulose claim 4 , polysaccharide gum claim 4 , silicate claim 4 , acrylic polymer coupled to a hydrophobic chain claim 4 , modified starch and/or polyacrylamide.6. The dermatological composition as defined by claim 5 , wherein the amount of additional gelling agent ranges from 0.01% to 20% by weight claim 5 , with respect to the total weight of the composition.7. The dermatological composition as defined by claim 1 , comprising from 0.0001% to 20% of said at least one retinoid by weight claim 1 , with respect to the total weight of the composition.8. The dermatological composition as defined by ...

Подробнее
09-01-2014 дата публикации

Antifungal serum

Номер: US20140011871A1
Автор: Turner Rockhill
Принадлежит: Ad Lunam Labs Inc

The subject invention is based upon the discovery that an antifungal agent can be delivered through the fingernail or the toenail of an infected human to treat onychomycosis by dissolving or dispersing the antifungal agent in a solvent system which is comprised of a combination of an alkyl lactate and Simmondsia chinesis seed oil. In accordance with this invention the antifungal agent is absorbed by and incorporated into the nail matrix by diffusing through the epithelium of the nail bed to reach the nail bed hyperkeratosis. The antifungal agent additionally penetrates into the ventral surface of the nail plate. The subject invention more specifically discloses an antifungal serum which is comprised of (1) an alkyl lactate, such as isoamyl lactate, (2) Simmondsia chinesis seed oil, and (3) an antifungal agent, such as tolnaftate or undecylenic acid.

Подробнее
16-01-2014 дата публикации

METHOD OF TREATING ANDROGEN RECEPTOR (AR) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS)

Номер: US20140018433A1
Принадлежит:

This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and/or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention. 56-. (canceled)7. The method of or , wherein said breast cancer is a breast cancer that has failed selective estrogen receptor modulator SERM (tamoxifen , toremifene) , aromatase inhibitor , trastuzumab (Herceptin , ado-trastuzumab emtansine) , pertuzumab (Perjeta) , lapatinib , exemestane (Aromasin) , pertuzumab (Perjeta) , exemestance (Aromasin) , bevacizumab (Avastin) , and/or fulvestrant treatments.1213-. (canceled)14. The method of claim 8 ...

Подробнее
16-01-2014 дата публикации

TREATMENT OF INFLAMMATORY AND INFECTIOUS SKIN DISORDERS

Номер: US20140018437A1

Disclosed herein is a composition comprising of resveratrol and/or derivatives thereof and/or functionally related compounds and benzoyl peroxide and/or derivatives thereof and/or functionally related compounds for the treatment of acne and other inflammatory or infectious skin disorders. Also disclosed are methods of treating acne and other inflammatory and infectious skin disorders using the compositions described herein. 1. A topical formulation comprising an effective amount of resveratrol and/or derivative(s) thereof and/or functionally related compound(s) in combination with an effective amount of benzoyl peroxide and/or its derivative(s) and/or functionally related compound(s).2. The topical formulation according to claim 1 , wherein the formulation comprises trans-3 claim 1 ,4′ claim 1 ,5 trihydroxystilbene (trans-resveratrol) and benzoyl peroxide.3. The topical formulation according to claim 1 , wherein the formulation comprises trans-resveratrol and benzoyl peroxide and/or its derivative(s) and/or functionally related compound(s).4. The topical formulation according to wherein the resveratrol derivative is selected from the group consisting of cis-3 claim 1 ,4′ claim 1 ,5-trihydroxystilbene claim 1 , 3 claim 1 ,4-dihydroxy-4′-methoxystilbene; 3 claim 1 ,5-dimethoxv-4′-hydroxystilbene; 3 claim 1 ,4′5-trimethoxystilbene: α claim 1 ,β-dihydro-3 claim 1 ,4′ claim 1 ,5-trihydroxystilbene: cis-piceid; trans-piceid claim 1 , pterostilbene; epsilon-viniferin; alpha-viniferin; delta-viniferin; resveratrol dimer; 5 claim 1 ,4′-dihydroxy-3-O-methoxvstilbene; 3 claim 1 ,4-dihydroxy-4′-O-methoxystilbene; and resveratroloside.517-. (canceled)18. The topical formulation according to wherein the resveratrol derivative is a derivative of resveratrol that arises from substituting different functional R groups claim 1 , wherein R is hydrogen claim 1 , methyl claim 1 , Calkyl claim 1 , hydroxy claim 1 , or Calkoxy claim 1 , at one or more various positions around the central ...

Подробнее
20-02-2014 дата публикации

TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT

Номер: US20140050792A1
Автор: Chang Yunik, Dow Gordon J.
Принадлежит: Dow Pharmaceutical Sciences, Inc.

An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. 1. A method for treating acne comprising applying once a day for up to 12 weeks to the skin of a patient in need thereof a surfactant-free , aqueous 2.5% w/w benzoyl peroxide gel that is suitable for topical application to the skin and that comprises water , a water-miscible organic solvent , 2.5% w/w benzoyl peroxide and 1.2% w/w clindamycin phosphate , and a suspension of benzoyl peroxide , the concentration (w/w) of the organic solvent being between one and four times the concentration (w/w) of the benzoyl peroxide , and the ratio of the water to the organic solvent being at least 12:1.2. The method of claim 1 , in which the clindamycin phosphate is dissolved in the gel.3. The method of claim 2 , in which the water-miscible organic solvent is propylene glycol.4. The method of claim 3 , in which the concentration of the water-miscible organic solvent is two times the concentration of the benzoyl peroxide.5. The method of claim 2 , in which the gelling agent is a carboxyvinyl polymer.6. The method of claim 3 , in which the benzoyl peroxide has a mean particle size of between 2.5 and 30 microns.7. The ...

Подробнее
27-02-2014 дата публикации

Hyaluronate Compositions

Номер: US20140057859A1
Автор: Lewis Robert
Принадлежит: Cypress Pharmaceuticals, Inc.

The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same. 1. A composition suitable for topical administration to a mammalian subject , the composition comprising , by mass , from about 0.05% to about 5% sodium hyaluronate and a pharmaceutically acceptable excipient , wherein from about 0.001 wt % to about 5 wt % of the sodium hyaluronate in the composition has a molecular weight ranging between about 0.01 megadaltons and about 0.4 megadaltons;and wherein the pharmaceutically acceptable excipient is predominantly in the liquid phase at ambient temperature.2. The composition of claim 1 , wherein from about 0.001 wt % to about 5 wt % of the sodium hyaluronate in the composition has a molecular weight ranging between about 0.5 megadaltons and about 1.6 megadaltons.3. The composition of claim 2 , wherein from about 50 wt % to about 95 wt % of the sodium hyaluronate in the composition has a molecular weight ranging between about 1.7 megadaltons and about 4.0 megadaltons.4. The composition according to claim 1 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of water claim 1 , an alcohol claim 1 , an oil claim 1 , glycerin claim 1 , polyethylene glycol claim 1 , lanolin claim 1 , petrolatum claim 1 , wax claim 1 , and poloxamer.5. (canceled)6. (canceled)7. The composition according to claim 4 , wherein the pharmaceutically acceptable excipient is water.8. The composition of claim 7 , wherein the ratio of the mass of water to the total mass of the composition ranges from about 60% to about 99.9%.916-. (canceled)17. The composition of claim 1 , wherein the composition further comprises an agent selected from the group consisting of an antifungal agent claim 1 , an antibiotic claim 1 , an anti-acne agent claim 1 , an antiviral agent claim 1 , ...

Подробнее
20-03-2014 дата публикации

Treatment of cerebral ischemia

Номер: US20140080873A1
Принадлежит: Pharnext SA

The present invention relates to new compositions and methods for protecting neuronal cells from ischemic or hypoxic events. More precisely, this invention provides new combinatorial therapies that efficiently protect neuronal cells from ischemia or hypoxia.

Подробнее
07-01-2021 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING SILICA MICROSPHERES

Номер: US20210000741A1
Принадлежит:

Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation. 120-. (canceled)21. A sustained release composition for topical application of pharmaceuticals comprising:silica microspheres impregnated with benzoyl peroxide, wherein the composition comprises about 5% w/w benzoyl peroxide and silica; and said composition is formulated for sustained release of said benzoyl peroxide.22. The sustained release composition of claim 21 , wherein some of the active ingredients are free in the composition claim 21 , and the active ingredients impregnated in the silica microspheres provides sustained release of the active ingredients.23. The sustained release composition of claim 21 , wherein the composition is formulated as a foam.24. The sustained release composition of claim 21 , wherein said sustained release composition is formulated in a semisolid form.25. The sustained release composition of claim 24 , wherein the semisolid form is a gel claim 24 , a cream claim 24 , a paste claim 24 , a lotion claim 24 , an ointment claim 24 , a shampoo claim 24 , a semisolid powder or a suspension.26. The sustained release composition of claim 21 , wherein the silica microspheres have a mean microsphere size in the range of 0.5 micron to 40 microns.27. The sustained release composition of claim 21 , wherein the silica microspheres have a mean microsphere size in the range of 1 micron to 20 microns.28. The sustained release composition of further comprising one or more of a solvent claim 21 , an antioxidant claim 21 , an antimicrobial preservative claim 21 , an emulsifier claim 21 , and water.29. The sustained release composition of claim 28 , wherein the solvent is selected from the group consisting of ...

Подробнее
07-01-2016 дата публикации

BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS

Номер: US20160000736A1
Принадлежит:

The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination. 1. A method for treating multiple sclerosis in a subject in need thereof , comprising administering to said subject an effective amount of baclofen and acamprosate , or pharmaceutically acceptable salt(s) or derivative(s) thereof.2. The method of claim 1 , comprising administering an effective amount of at least one further compound selected from sulfisoxazole claim 1 , methimazole claim 1 , prilocaine claim 1 , dyphylline claim 1 , quinacrine claim 1 , carbenoxolone claim 1 , aminocaproic acid claim 1 , cabergoline claim 1 , diethylcarbamazine claim 1 , cinacalcet claim 1 , cinnarizine claim 1 , eplerenone claim 1 , fenoldopam claim 1 , leflunomide claim 1 , levosimendan claim 1 , sulodexide claim 1 , terbinafine claim 1 , zonisamide claim 1 , etomidate claim 1 , phenformin claim 1 , trimetazidine claim 1 , mexiletine claim 1 , ifenprodil claim 1 , moxifloxacin claim 1 , bromocriptine or torasemide claim 1 , or pharmaceutically acceptable salt(s) thereof.5. The method of claim 1 , wherein baclofen and acamprosate claim 1 , or the pharmaceutically acceptable salt(s) or derivative(s) thereof claim 1 , are the only active agents administered for treating multiple sclerosis.6. The method of claim 1 , wherein said derivative(s) has(ve) a Tanimoto similarity index greater than 0.4 with either baclofen or acamprosate claim 1 , respectively claim 1 , and a protective activity against glutamate toxicity.7. The method of claim 1 , wherein ...

Подробнее
03-01-2019 дата публикации

METHODS OF TREATING ACNE USING NANOEMULSION COMPOSITIONS

Номер: US20190000761A1
Принадлежит: NanoBio Corporation

The present invention relates to methods for treating and preventing acne or infection in a subject comprising topically administering to the subject in need thereof an anti-acne nanoemulsion composition, comprising CPC or BKC as a cationic agent. 1P. acnes. A method of treating and/or preventing acne by reducing the amount of present in a human subject in need thereof , wherein the method comprises topically administering to the subject a nanoemulsion , wherein:(a) the nanoemulsion comprises droplets having an average diameter of less than about 3 microns; (i) cetylpyridinium chloride (CPC) is present at a concentration of about 0.1% up to about 0.4%; or', '(ii) benzalkonium chloride (BKC) is present at a concentration of about 0.05% up to about 1.6%., '(b) the nanoemulsion droplets comprise an oil phase with at least one oil, and an aqueous phase comprising at least one cationic surfactant, at least one organic solvent, and water, wherein the cationic surfactant is2. The method of claim 1 , wherein:(a) the nanoemulsion droplets target the pilosebaceous gland; and/or(b) the nanoemulsion droplets enter the pilosebaeous gland (unit), hair follicle, epidermis, dermis, or a combination thereof.3. The method of claim 1 , wherein the nanoemulsion is at room temperature at the time of administration.4. The method of claim 1 , wherein prior to application the nanoemulsion is warmed to a temperature selected from the group consisting of about 30° C. or warmer claim 1 , about 31° C. or warmer claim 1 , about 32° C. or warmer claim 1 , about 33° C. or warmer claim 1 , about 34° C. or warmer claim 1 , about 35° C. or warmer claim 1 , about 36° C. or warmer claim 1 , and about 37° C.5. The method of claim 1 , wherein CPC is present at a concentration selected from the group consisting of about 0.10% claim 1 , about 0.11% claim 1 , about 0.12% claim 1 , about 0.13% claim 1 , about 0.14% claim 1 , about 0.15% claim 1 , about 0.16% claim 1 , about 0.17% claim 1 , about 0.18% claim ...

Подробнее
07-01-2021 дата публикации

METHODS AND COMPOSITIONS FOR TREATMENT OF EPILEPTIC DISORDERS

Номер: US20210000805A1
Автор: DURING Matthew
Принадлежит:

Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof. 1. A method of treating status epilepticus comprising administering to a patient in need thereof a pharmaceutical composition comprising ganaxolone or a pharmaceutically acceptable salt thereof.2. The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof twice daily.3. The method of claim 1 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof three times daily.4. The method of claim 6 , wherein the patient is administered ganaxolone or a pharmaceutically acceptable salt thereof in an amount of up to 1 claim 6 ,800 mg/day.5. The method of claim 1 , wherein the pharmaceutical composition is an oral capsule.6. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension.7. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof.8. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof and is administered three times daily.9. The method of claim 1 , wherein the pharmaceutical composition is an oral suspension comprising 50 mg/ml ganaxolone or a pharmaceutically acceptable salt thereof administered three times daily wherein the patient is administered an amount of up to 1 claim 1 ,800 mg/day10. The method of claim 1 , wherein the patient is administered 600 mg ganaxolone or a pharmaceutically acceptable salt thereof.11. The method of claim 1 , wherein the patient is administered 600 mg ganaxolone or a pharmaceutically acceptable salt thereof three times daily.12. The method of claim 1 , wherein the patient is administered 50 mg ganaxolone or a pharmaceutically acceptable salt thereof.13. The method of claim 1 , wherein the ...

Подробнее
05-01-2017 дата публикации

Methods for treating or preventing fatigue

Номер: US20170000756A1
Принадлежит: SK Biopharmaceuticals Co Ltd

The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.

Подробнее
05-01-2017 дата публикации

THERAPEUTIC APPLICATION OF (BOC)2-CREATINE

Номер: US20170000757A1
Принадлежит:

A creatine derivative, (Boc)2-creatine, is used as a medicament, in particular in a therapeutic antitumor treatment. I (Boc)2-creatine. 1. The compound (Boc)-creatine for use as a medicament.2. The compound (Boc)-creatine for use according to claim 1 , for the treatment of tumor diseases.3. The compound (Boc)-creatine for use according to claim 1 , in combination with one or more other antitumor agents.4. The compound (Boc)-creatine for use according to claim 1 , in a pharmaceutical dosage form capable of providing a (Boc)-creatine concentration comprised within the range of from 0.25 to <2 mM.5. The compound (Boc)-creatine for use according to claim 4 , in a pharmaceutical dosage form capable of providing a (Boc)-creatine concentration comprised within the range of from 0.25 to 1.9 mM.6. The compound (Boc)-creatine for use according to claim 4 , in a pharmaceutical dosage form capable of providing a (Boc)-creatine concentration comprised within the range of from 0.25 to 1 mM. The present invention generally falls within the therapeutic field and more particularly within the field of therapy for neoplastic pathologies.The enzyme creatine kinase (EC 2.7.3.2, CK) plays an essential role in the energy metabolism of cells (Saks et al 1975; Seraydarian and Abbott 1976). The said enzyme is ubiquitous and capable of transferring phosphate groups from ATP to creatine and from phosphocreatine to ADP, allowing for the recharging of ATP. In the proximity of mitochondria, the enzyme creatine kinase catalyzes the phosphorylation of creatine, thereby generating ADP and phosphocreatine. In the cell areas that require more energy, creatine kinase transfers the phosphate group from phosphocreatine to ADP to restore ATP, thus supporting the cell's energy requirements.The enzyme creatine kinase has a molecular weight of approximately 60KDa and is made of four subunits: two cytosolic, M-CK and B-CK, and two mitochondrial, “ubiquitous” uMt-CK and “sarcomeric” sMt-CK (Joseph et al 1997; ...

Подробнее
05-01-2017 дата публикации

GEL COMPOSITION FOR TREATMENT OF COMMON ACNE COMPRISING A COMBINATION OF BENZOYL PEROXIDE AND ADAPALENE AND/OR ADAPALENE SALT

Номер: US20170000758A1
Принадлежит:

Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C. 134-. (canceled)35. A physiologically acceptable aqueous gel composition for treatment of common acne comprising: 0.05% to 1% adapalene and/or at least one pharmaceutically acceptable salt thereof, and', '2.5% to 5% dispersed benzoyl peroxide; and, '(1) anti-acne actives consisting of(2) 2% to 5% polyacrylamide/C13-14 isoparaffin/laureth-7 gelling agent,said percentages being based on the weight of the total aqueous gel composition for treatment of common acne,36. The physiologically acceptable aqueous gel composition of comprising 3.5% to 4% polyacrylamide/C13-14 isoparaffin/laureth-7 gelling agent claim 35 , said percentages being based on the weight of the total aqueous gel composition for treatment of common acne.37. The physiologically acceptable aqueous gel composition of comprising anti-acne actives consisting of:0.1% adapalene and/or at least one pharmaceutically acceptable salt thereof,and2.5% dispersed benzoyl peroxidesaid percentages being based on the weight of the total aqueous gel composition for treatment of common acne.38. The physiologically acceptable aqueous gel composition of comprising anti-acne actives consisting of:0.3% adapalene and/or at least one pharmaceutically acceptable salt thereof,and2.5% ...

Подробнее
03-01-2019 дата публикации

ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS

Номер: US20190000826A1
Принадлежит: CHASE PHARMACEUTICALS CORPORATION

The present invention relates to a pharmaceutical composition comprising propiverine, trospium or glycopyrrolate; and a non-anticholinergic antiemetic agent. It is also related to a pharmaceutical composition comprising a high dose of solifenacin or a pharmaceutically acceptable salts thereof; and a non-anticholinergic antiemetic agent. Pharmaceutical compositions containing high dose of nsPAChA for use for increasing the AChEI blood concentrations and for combating neurodegeneration are also described. The invention also relates to a method for inducing neuroprotection and combating neurodegeneration in a patient suffering from Alzheimer type dementia as well as to a method for increasing the blood levels of an acetyl choline esterase inhibitor (AChEI) in a human subject treated with an AChEI dose. 1. A pharmaceutical composition comprising a nsPAChA selected from the group consisting of propiverine and pharmaceutically acceptable salts thereof, in an amount which is equivalent to from 15 mg to 120 mg of propiverine hydrochloride; trospium pharmaceutically acceptable salts, in an amount which is equivalent to from 20 mg to 480 mg of trospium chloride; and glycopyrrolium pharmaceutically acceptable salts, in an amount which is equivalent to from 2 mg to 16 mg of glycopyrronium bromide; and (b) a non-anticholinergic antiemetic agent (naAEA); in admixture with a pharmaceutical carrier. The invention relates to a pharmaceutical composition comprising (a) a high dose of a non-selective peripheral anticholinergic agent (nsPAChA) selected from the group consisting of propiverine and pharmaceutically acceptable salts thereof, trospium and pharmaceutically acceptable salts thereof, glycopyrrolium and pharmaceutically acceptable salts thereof, and solifenacine and pharmaceutically acceptable salts thereof; (b) a non-anticholinergic antiemetic agent (naAEA); in admixture with a pharmaceutical carrier; and (c) a high dose of an acetylcholine esterase inhibitor (AChEI). This ...

Подробнее
07-01-2016 дата публикации

CENTRAL ADMINISTRATION OF STABLE FORMULATIONS OF THERAPEUTIC AGENTS FOR CNS CONDITIONS

Номер: US20160000926A1

The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS. 1. A pharmaceutical composition comprising a central nervous system (CNS) therapeutic agent and a solubility enhancing agent , wherein the CNS therapeutic agent maintains solubility in said composition for at least two months at physiological temperature and pH.2. The pharmaceutical composition of claim 1 , wherein the CNS therapeutic agent is active in the treatment of a CNS condition or disorder selected from the group consisting of epilepsy claim 1 , schizophrenia claim 1 , Closed Head Injury Spectrum claim 1 , Alzheimer's Spectrum claim 1 , sleep disorders spectrum claim 1 , depression claim 1 , anxiety spectrum claim 1 , bipolar disorder and multiple sclerosis.3. The pharmaceutical composition of claim 1 , wherein the CNS therapeutic agent is active in the treatment of epilepsy.4. The pharmaceutical composition of claim 3 , wherein the CNS therapeutic agent is an anti-epilepsy agent that acts on the GABA system claim 3 , a Sodium Channel claim 3 , and/or a Calcium Channel.5. The pharmaceutical composition of claim 3 , wherein the CNS therapeutic agent is selected from the group consisting of: ...

Подробнее
04-01-2018 дата публикации

PEROXIDE DISPERSIONS

Номер: US20180000948A1
Принадлежит:

The viscosity of aqueous dispersions of normally solid organic peroxides may be advantageously lowered through the use of surfactants which are polyglyceryl esters of C6-C12 fatty acids. The reduction in viscosity facilitates milling the peroxides to reduce particle size and also provides dispersions of small particle size peroxides which may be readily poured or pumped. 1. An aqueous pumpable or pourable dispersion comprising a) about 35% by weight or more of water-insoluble , solid benzoyl peroxide having an average particle size of less than 5 μm and b) 0.1 to 2.0 weight percent of surfactant having an HLB value of 12 to 18 and which is a polyglyceryl ester of one or more saturated C6-C18 fatty acids selected from the group consisting of octanoic acid , decanoic acid , and mixtures thereof.2. The aqueous pumpable or pourable dispersion of claim 1 , wherein the polyglyceryl ester of one or more fatty acids contains a polyglycerol moiety having 8 to 12 glycerol repeating units on average.3. The aqueous pumpable or pourable dispersion of claim 1 , wherein the surfactant is based on a polyglyceryl having hydroxyl groups with from about 25% to about 60% of the hydroxyl groups of the polyglyceryl being esterified.4. The aqueous pumpable or pourable dispersion of claim 1 , wherein the surfactant is selected from the group consisting of polyglyceryl-10 caprylate/caprate claim 1 , polyglyceryl-10 caprylate claim 1 , and polyglyceryl-10 laurate claim 1 , and mixtures thereof.5. The aqueous pumpable or pourable dispersion of claim 1 , wherein the surfactant is a polyglyceryl-10 caprylate/caprate.6. The aqueous pumpable or pourable dispersion of claim 1 , wherein the surfactant is a food grade surfactant and/or a pharmaceutically acceptable surfactant.7. The aqueous pumpable or pourable dispersion of claim 1 , additionally comprising a macromolecular gelling agent.8. The aqueous pumpable or pourable dispersion of claim 7 , wherein the macromolecular gelling agent crosslinks ...

Подробнее
04-01-2018 дата публикации

PRODUCT, OR ACTIVE AGENT, OR COMPOSITION FOR THE CARE OF THE BREASTS IN A PREMENSTRUAL OR MENSTRUAL PERIOD OR FOR THE CARE OF THE SYMPTOMATOLOGY OF MASTODYNIA

Номер: US20180002281A1
Принадлежит:

A method for caring for or treating the breasts during premenstrual or menstrual phases and for the care or treatment of the symptomatology of mastodynia, comprising a step of selecting or identifying women needing care or treatment of the breasts, or suffering from symptomatology of mastodynia, and a step of applying to the skin areas in need thereof an effective amount of a product, active agent or composition, comprising peroxidized lipids or a peroxidised oil, or consisting essentially of peroxidized lipids or of a peroxidised oil. 1. A method for caring for or treating the breasts during premenstrual or menstrual phases and also for the care or treatment of the symptomatology of mastodynia , comprising a step of selecting or identifying women needing care or treatment of the breasts , or suffering from symptomatology of mastodynia , and a step of applying to the skin areas in need thereof an effective amount of a product , active agent or composition , comprising peroxidized lipids or a peroxidised oil , or consisting essentially of peroxidized lipids or of a peroxidised oil.2. The method of claim 1 , wherein the peroxidised lipids or peroxidised oil comprise/s or are/is consisting of peroxidized glycerol triesters.3. The method of claim 1 , wherein the peroxidised lipids or peroxidised oil are/is obtained from a vegetable oil chosen from a corn vegetable oil claim 1 , a soya vegetable oil claim 1 , a sweet almond vegetable oil claim 1 , a hazelnut vegetable oil claim 1 , a peanut vegetable oil claim 1 , a grapeseed vegetable oil claim 1 , a sesame vegetable oil and a safflower vegetable oil claim 1 , or a mixture of these oils in any proportion(s).4. The method of claim 1 , wherein the peroxidized lipids/peroxidised oil have/has a degree of peroxidation of between 5 and 600 milliequivalents per kg.6. The method of claim 1 , wherein the product claim 1 , active agent or composition is consisting essentially of the peroxidized lipids or peroxidised oil.7. The ...

Подробнее
07-01-2021 дата публикации

MOTUPORAMINE DERIVATIVES AS ANTIMICROBIAL AGENTS AND ANTIBIOTIC ENHANCERS AGAINST RESISTANT GRAM-NEGATIVE BACTERIA

Номер: US20210002206A1
Принадлежит:

Motuporamine agents having antimicrobial activity and uses thereof. 1. A composition comprising a combination of an effective amount of one or more compounds selected from the group consisting of 4a , 4b , 5a , 5b , 6a , 6b , 7a , 7b , 8a , 8b , 9a , 9b , 10 , 11a , 11b , 11c , 12a , 15 , 16a , 16b , 16c , and 50; and an effective amount of an antibiotic.2. The composition of claim 1 , wherein the antibiotic comprises amoxicillin claim 1 , doxycycline claim 1 , erythromycin claim 1 , chloramphenicol claim 1 , cephalexin claim 1 , ciprofloxacin claim 1 , clindamycin claim 1 , methicillin claim 1 , metronidazole claim 1 , penicillin claim 1 , rifampicin claim 1 , azithromycin claim 1 , sulfamethoxazole/trimethoprim claim 1 , amoxicillin/clavulanate claim 1 , levofloxacin claim 1 , or vancomycin.3. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.6. A compound having antibiotic activity claim 1 , wherein the compound is 16a claim 1 , 16b claim 1 , 16c or 50 claim 1 , or a pharmaceutically acceptable salt thereof. Antimicrobial resistance threatens the prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses, and fungi. An increasing number of governments around the world are devoting efforts to this problem, which is so serious that it threatens the achievements of modern medicine. Far from being an apocalyptic fantasy, a post-antibiotic era in which common infections and minor injuries can kill is a real possibility for the 21st century. A recent WHO report makes a clear case that resistance to common bacteria has reached alarming levels in many parts of the world, and that in some settings few, if any, of the available treatment options remain effective for common infections. Another important finding of the report is that surveillance of antibacterial resistance is neither coordinated nor harmonized and there are many gaps in information regarding bacteria of major public health ...

Подробнее
12-01-2017 дата публикации

Pharmaceutical compositions comprising silica microspheres

Номер: US20170007539A1
Принадлежит: Perrigo Israel Pharmaceuticals Ltd

Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

Подробнее
14-01-2016 дата публикации

STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE

Номер: US20160008476A1
Принадлежит:

The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HPMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form. 16-. (canceled)7. A method of treating a disorder selected from the group consisting of epilepsy , neuropathic pain , tremor , epileptogenesis , neuroprotection , schizophrenia , non-schizophrenic psychoses , dementia , behavioral disturbances in mental retardation and autism , bipolar mania , depression , and anxiety , in a mammal in need thereof , which comprisesadministering to the mammal a therapeutically-effective amount of a pharmaceutical composition in the form of a stabilized aqueous suspension,wherein the stabilized aqueous suspension comprises a) from about 10 to about 30 mg/ml carisbamate; b) from about 5.0 to about 15.0 mg/ml of hypromellose; and c) water, andwherein the therapeutically-effective amount of carisbamate is administered in a total daily dose ranging from 50 mg to 1,200 mg.8. The method of claim 7 , wherein said disorder is epilepsy.9. The method of claim 8 , wherein the method comprises administering to a pediatric patient.10. The method of claim 7 , wherein said disorder is neuropathic pain.11. The method of claim 7 , wherein the pharmaceutical composition further comprises one or more agents selected from the group consisting of a suspending agent claim 7 , a wetting agent claim 7 , a preservative agent claim 7 , a buffering agent claim 7 , a sweetening agent claim 7 , and a flavoring substance.12. The method of claim 7 , wherein the pharmaceutical composition further comprises a suspending agent.13. The method of claim 12 , wherein the suspending agent is selected from the group consisting of methyl cellulose claim 12 , sodium carmellose claim 12 , hypromellose claim 12 , polyvinylpyrrolidone claim 12 , alginate ...

Подробнее
14-01-2021 дата публикации

HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY

Номер: US20210008022A1
Принадлежит:

Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, 14-. (canceled)68-. (canceled)91. An anti-tumor drug or immunomodulation drug , comprising an effective amount of a compound as shown in claim , pharmaceutically acceptable salts thereof , hydrates thereof , solvates thereof or a pharmaceutical composition thereof as an active component.10. The anti-tumor drug or immunomodulation drug of claim 9 , wherein the drug releases 2-tert-butyl-4-methyoxyphenyl.141. A process for treating a tumor or for immunomodulation in a subject comprising administering to a subject an effective amount of a compound as shown in claim claim 9 , pharmaceutically acceptable salts thereof claim 9 , hydrates claim 9 , or solvates thereof.15. The process according to claim 14 , wherein the compound releases 2-tert-butyl-4-methoxyphenol.161. A process of controlling 2-tert-butyl-4-methoxyphenol in a subject claim 14 , comprising administering to the subject an effective amount of a compound as shown in claim claim 14 , pharmaceutically acceptable salts thereof claim 14 , hydrates claim 14 , or solvates thereof. The present application is a divisional of U.S. Non-Provisional patent application Ser. No. 16/069,814, entitled “HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY,” and filed on Jul. 12, 2018. U.S. Non-Provisional patent application Ser. No. 16/069,814 is a U.S. National Phase of International Patent Application Serial No. PCT/CN2017/074386, entitled “HYDROQUINONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION IN TUMOUR RESISTANCE OR IMMUNOMODULATION,” filed on Feb. 22, 2017. International Patent Application Serial No. PCT/CN2017/074386 claims priority to Chinese Patent Application No. 201610037849.5, filed on Jan. 20, 2016. The entire contents of each of the above-cited ...

Подробнее
27-01-2022 дата публикации

Compositions and methods for remediating chemical warfare agent exposed skin

Номер: US20220023174A1
Автор: Edwin Neas, Scott NOBLITT
Принадлежит: Armis Biopharma Inc

The present invention relates to chemical and biological warfare agent decontaminating compositions and methods for using the same to decontaminate animal skin and wounds thereon exposed to the agents. The compositions may comprise a peracid, a hydroperoxide, and a peroxyacid.

Подробнее
27-01-2022 дата публикации

ISOPROPYLCARBONATE BENZOYL PEROXIDE COMPOSITIONS AND METHODS OF USE

Номер: US20220023250A1
Принадлежит: Galderma Holding SA

Described herein are compositions comprising (i) Isopropylcarbonate Benzoyl Peroxide, (ii) an opacifier, and (iii) and a preserving agent that have good physical, chemical and microbiological stability and corresponding methods of use. 1. A topically applicable composition comprising:i) Isopropylcarbonate Benzoyl Peroxide;ii) an opacifier; andiii) a preserving agent.2. The topically applicable composition of claim 1 , wherein the composition comprises about 0.1% to about 10% by weight of Isopropylcarbonate Benzoyl Peroxide.3. The topically applicable composition of claim 1 , wherein the opacifier is bismuth oxychloride claim 1 , titanium dioxide claim 1 , fluorphlogopite claim 1 , mica claim 1 , iron oxide claim 1 , nylon polymer claim 1 , polymethyl methacrylate claim 1 , boron nitride claim 1 , kaolin claim 1 , glycol distearate claim 1 , styrene copolymer claim 1 , a fatty alcohol claim 1 , or any combination thereof.4. The topically applicable composition of claim 1 , wherein the composition comprises about 0.1% to about 2.5% by weight of the opacifier.5. The topically applicable composition of claim 1 , wherein the preserving agent is phenoxyethanol claim 1 , potassium sorbate claim 1 , benzyl alcohol claim 1 , methyl paraben claim 1 , chlorhexidine digluconate claim 1 , chloroxylenol claim 1 , chlorphenesin claim 1 , dehydroacetic acid claim 1 , diazolidinyl urea claim 1 , DMDM hydantoin claim 1 , ethylparaben claim 1 , iodopropynyl butylcarbamate claim 1 , methylisothiazolinone claim 1 , propyllparaben claim 1 , phenoxyethanol claim 1 , phenoxyisopropanol claim 1 , polyaminopropyl biguianide claim 1 , sodium benzoate claim 1 , salicylic acid claim 1 , or any combination thereof.6. The topically applicable composition of claim 1 , wherein the composition comprises about 0.1% to about 0.8% by weight of the preserving agent.7. The topically applicable composition of further comprising a surfactant selected from the group consisting of docusate sodium ( ...

Подробнее
10-01-2019 дата публикации

METHOD FOR TREATING A PROTOZOAL INFECTION

Номер: US20190008853A1
Принадлежит:

A method for reducing motility and number of cells, said method comprising contacting the cells with an effective amount of a composition, the composition comprising a combination of metronidazole and itraconazole, wherein the effective amount is sufficient to reduce motility of the cells. 1L. donovaniL. donovaniL. donovani. A method for reducing motility and number of cells, said method comprising contacting the cells with an effective amount of a composition, the composition comprising a combination of metronidazole and itraconazole, wherein the effective amount is sufficient to reduce motility of the cells. This application is a divisional of U.S. patent application Ser. No. 15/241,308 filed Aug. 19, 2016, which is a divisional of U.S. patent application Ser. No. 13/815,664 filed Mar. 14, 2013 the disclosures of which are hereby incorporated by reference in their entireties.Strikingly, a large number of serious chronic diseases (such as cardiovascular disease, diabetes, obesity, hyperlipidemia, PCOS and hypertension) have been observed to cluster in patients. Such clustering can be identified in as many as one in five people on the planet and its prevalence increases with age. The problem is particularly acute in industrialized countries. Thus, chronic diseases such as cardiovascular disease, diabetes, obesity, hyperlipidemia, and hypertension, represent serious causes of polypharmacy, morbidity and reduced longevity. They also pose tremendous economic burdens on individuals, families and societies. Therefore, the identification of compositions and formulations capable of preventing or treating one or a combination of these disorders is desirable.In non-industrialized countries, infectious and parasitic diseases similarly threaten not only the lives of individuals, but the economic viability of families, communities, and societies as a whole. For example, protozoal illnesses continue to account for significant morbidity and mortality, especially in the tropical ...

Подробнее
10-01-2019 дата публикации

Method and Therapeutic/Cosmetic Topical Compositions for the Treatment of Rosacea and Skin Erythema Using A1-Adrenoceptor Agonists

Номер: US20190008857A1
Принадлежит:

The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α-adrenergic receptor (α-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin. 124.-. (canceled)25. A method of treating or preventing rosacea and the symptoms associated therewith , the method comprising topically administering to the skin of a patient in need of such treatment or prevention , a composition comprising an agent selected from an alpha-2 adrenoreceptor agonist , a pharmaceutically acceptable salt thereof , or a combination thereof.26. The method of claim 25 , wherein the composition comprises about 0.01% to about 20% of the agent.27. The method of claim 25 , wherein the composition comprises about 0.05% to about 30% of the agent.28. The method of claim 25 , wherein the composition comprises about 0.1% to about 10% of the agent.29. The method of claim 25 , wherein the agent is administered in a therapeutically effective amount.30. The method of claim 25 , wherein the composition further comprises a pharmaceutically acceptable carrier.31. The method of claim 30 , wherein the composition comprises about 50% to about 99.999% of the carrier.32. The method of claim 30 , wherein the composition comprises about 70% to about 99.99% of the carrier.33. The method of claim 30 , wherein the carrier is a hydrophilic gelling agent.34. The method of claim 30 , wherein the carrier is selected from a carboxyvinyl polymer claim 30 , an acrylic copolymer claim 30 , polyacrylamide claim 30 , polysaccharide or a combination thereof.35. The method of claim 25 , wherein the composition further comprises a ...

Подробнее
14-01-2021 дата публикации

INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS)

Номер: US20210009511A1
Принадлежит:

A series of phenelzine analogs comprising a phenelzine scaffold linked to an aromatic moiety and their use as inhibitors of lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) is provided. The presently disclosed phenelzine analogs exhibit potency and selectivity for LSD1 versus MAO and LSD2 enzymes and exhibit bulk, as well as, gene specific histone methylation changes, anti-proliferative activity in several cancer cell lines, and neuroprotection in response to oxidative stress. Accordingly, the presently disclosed phenelzine analogs can be used to treat diseases, conditions, or disorders related to LSD1 and/or HDACs, including, but not limited to, cancers and neurodegenerative diseases. 16-. (canceled)89-. (canceled)11. (canceled)13. A pharmaceutical composition comprising a compound of Formula (IIb).14. The pharmaceutical composition of claim 13 , further comprising one or more additional therapeutic agents.15. The pharmaceutical composition of claim 14 , wherein the one or more additional therapeutic agents is selected from the group consisting of a histone deacetylase (HDAC) inhibitor claim 14 , a DNA methyltransferase (DNMT) inhibitor claim 14 , and combinations thereof.16. A method for inhibiting lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) claim 14 , the method comprising administering to a subject a compound of Formula (IIb) claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , in an amount effective to inhibit LSD1 or one or more HDACs.18. The method of claim 17 , wherein the disease claim 17 , disorder claim 17 , or condition associated with LSD1 and/or one or more histone deacetylases (HDACs) is a cancer.19. The method of claim 17 , wherein the treating of the disease claim 17 , disorder claim 17 , or condition associated with LSD1 and/or one or more histone deacetylases (HDACs) includes activating one or more tumor suppressors silenced in cancer by an epigenetic ...

Подробнее
14-01-2021 дата публикации

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

Номер: US20210009572A1
Принадлежит:

The present invention provides a compound having a cholinergic muscarinic Ml receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. 14. 2-[(3S ,4S)-4-Hydroxytetrahydro-2H-pyran-3-yl]-6-(4-methoxybenzyl)-4 ,5-dimethyl-2 ,3-dihydro-1H-isoindol-1-one , or a salt thereof.15. 4-Fluoro-2-[(3S ,4S)-4-hydroxytetrahydro-2H-pyran-3-yl]-5-methyl-6-[4-(1H-pyrazol-1-yl)benzyl]-2 ,3-dihydro-1H-isoindol-1-one , or a salt thereof.16. 2-((1S ,2S)-2-Hydroxycyclohexyl)-4 ,5-dimethyl-6-((6-methylpyridin-3-yl)methyl)isoindolin-1-one , or a salt thereof.17. A medicament comprising the compound according to or a salt thereof.18. The medicament according to claim 17 , which is a cholinergic muscarinic M1 receptor positive allosteric modulator.19. The medicament according to claim 17 , which is an agent for the prophylaxis or treatment of Alzheimer's disease claim 17 , schizophrenia claim 17 , pain claim 17 , sleep disorder claim 17 , Parkinson's disease dementia or dementia with Lewy bodies.20. The compound according to or a salt thereof for use in the prophylaxis or treatment of Alzheimer's disease claim 1 , schizophrenia claim 1 , pain claim 1 , sleep disorder claim 1 , Parkinson's disease dementia or dementia with Lewy bodies.21. A method of cholinergic muscarinic M1 receptor positive allosteric modulation in a mammal claim 1 , which comprises administering an effective amount of the compound according to or a salt thereof to the mammal.22. A method for the prophylaxis or treatment of Alzheimer's disease claim 1 , schizophrenia claim 1 , pain claim 1 , sleep disorder claim 1 , Parkinson's disease dementia or dementia with Lewy bodies in a mammal claim 1 , which comprises administering an effective amount of the compound according to or a salt thereof to the mammal.23. Use of the compound according to or a ...

Подробнее
21-01-2016 дата публикации

Phenyl Carbamate Compound and a Composition for Preventing or Treating a Nerve Gas-Induced Disease Comprising the Same

Номер: US20160015679A1
Автор: Choi Yong Moon
Принадлежит: Bio-Pharm Solutions, Co., Ltd.

The present invention relates to a composition for preventing or treating a nerve gas-induced disease comprising a phenyl carbamate compound and a method for preventing or treating a nerve gas-induced disease therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating various diseases caused by exposure to nerve gas.

Подробнее
21-01-2016 дата публикации

Phenyl Carbamate Compound and a Composition for Neuroprotection Comprising the Same

Номер: US20160015680A1
Автор: Choi Yong Moon
Принадлежит: Bio-Pharm Solutions, Co., Ltd.

The present invention relates to a composition for neuroprotection comprising a phenyl carbamate compound and a method for providing neuroprotection therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating various diseases associated with neurological injury. 2. The composition according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , Rand Rare each independently selected from the group consisting of hydrogen claim 1 , chlorine claim 1 , fluorine and iodine.5. The composition according to claim 1 , wherein the compound is selected from the group consisting of:(1) 1-(2-chlorophenyl)-1-hydroxypropyl-2-carbamate;(2) 1-(2-chlorophenyl)-1-hydroxybutyl-2-carbamate;(3) 1-(2-chlorophenyl)-1-hydroxy-3-methyl-butyl-2-carbamate;(4) 1-(2-chlorophenyl)-1-hydroxyhexyl-2-carbamate;(5) 1-(2-chlorophenyl)-1-hydroxypropyl-2-N-methylcarbamate;(6) 1-(2-chlorophenyl)-1-hydroxypropyl-2-N-propylcarbamate;(7) 1-(2-chlorophenyl)-1-hydroxypropyl-2-N-isopropylcarbamate;(8) 1-(2-chlorophenyl)-1-hydroxypropyl-2-N-cyclopropylcarbamate;(9) 1-(2-chlorophenyl)-1-hydroxypropyl-2-N-cyclohexylcarbamate;(10) 1-(2-chlorophenyl)-1-hydroxypropyl-2-N-benzylcarbamate;(11) 1-(2-chlorophenyl)-1-hydroxypropyl-2-N-bicyclo[2,2,1]heptanecarbamate;(12) 1-(2,4-dichlorophenyl)-1-hydroxypropyl-2-carbamate;(13) 1-(2,6-dichlorophenyl)-1-hydroxypropyl-2-carbamate;(14) 1-(2,4-dichlorophenyl)-1-hydroxybutyl-2-carbamate;(15) 1-(2,6-dichlorophenyl)-1-hydroxybutyl-2-carbamat;(16) 1-(2,4-dichlorophenyl)-1-hydroxy-3-methyl-butyl-2-carbamate;(17) 1-(2,6-dichlorophenyl)-1-hydroxy-3-methyl-butyl-2-carbamate;(18) 1-(2,4-dichlorophenyl)-1-hydroxyhexyl-2-carbamate;(19) 1-(2,6-dichlorophenyl)-1-hydroxyhexyl-2-carbamate;(20) 1-(2-chlorophenyl)-2-hydroxypropyl-1-carbamate;(21) 1-(2-chlorophenyl)-2-hydroxypropyl-1-N-methylcarbamate;(22) 1-(2-chlorophenyl)-2-hydroxypropyl-1-N-propylcarbamate;(23) 1-(2-chlorophenyl)-2-hydroxypropyl-1-N-isopropylcarbamate;(24 ...

Подробнее
21-01-2016 дата публикации

Methods for Treating Acne Vulgaris

Номер: US20160015744A1
Автор: Dabney Paul
Принадлежит:

Methods for treating acne vulgaris include providing a solution having a peroxide compound, the solution having an antimicrobial effect for reducing bacteria that cause acne vulgaris; topically administering a therapeutically effective amount of the solution to the patient; and once administered, exposing the solution to a wavelength of light that creates a synergistic antimicrobial effect with the solution and enhances the antimicrobial effect of the solution, thereby further reducing or eliminating the bacteria that cause acne vulgaris. The methods may decrease lesions and associated inflammation in patients infected with acne vulgaris,

Подробнее
21-01-2016 дата публикации

COMPOSITIONS AND METHODS FOR PHYSIOLOGICAL DELIVERY USING CANNABIDIOL

Номер: US20160015818A1
Автор: Taha Ashraf
Принадлежит: Medipath, Inc.

The present invention relates to compositions and methods for the administration of Cannabinoids to a patient, and in a specific embodiment, the compositions and methods may utilize or include cannabinoids, and one or more active pharmaceutical ingredients, wherein said composition is configured for transdermal or oral delivery.

Подробнее
17-01-2019 дата публикации

METHOD OF ACNE TREATMENT BY CONCOMITANT TOPICAL ADMINISTRATION OF BENZOYL PEROXIDE AND TRETINOIN

Номер: US20190015368A1
Принадлежит: SOL-GEL TECHNOLOGIES LTD.

The present disclosure relates to methods of treatment of acne in a patient in need thereof, comprising the concomitant once daily topical administration of from about 2% w/w to about 10% w/w of solid particulate benzoyl peroxide (BPO) and from about 0.01% w/w to about 0.1% w/w of solid particulate all trans retinoic acid (ATRA) for a period of up to 3 months, wherein the side-effects of the two actives are medically acceptable and wherein the therapeutic effect of BPO and ATRA is superior to the effect of each active administered alone. The concomitant administration may be carried out by once daily administration to a patient in need thereof of a single composition or of a first composition comprising BPO and a second composition comprising ATRA from a dual chamber dispenser or from two separate dispensers, mixed before applying on the skin of a patient in need thereof for up to 2 weeks, up to 1 month, preferably up to 2 months and more preferably up to 3 months. 1. A method of treatment of acne in a patient in need thereof , comprising the concomitant topical administration once daily for a period of up to 3 months of a stable composition , comprising from about 2% w/w to about 10% w/w of solid particulate benzoyl peroxide (BPO) and from about 0.01% w/w to about 0.1% w/w of solid particulate all trans retinoic acid (ATRA) ,wherein 90% of the solid particles of ATRA are in the range of 5-20 microns,wherein the side-effects of the two active agents BPO and ATRA are medically acceptable and wherein the therapeutic effect of BPO and ATRA is superior to the effect of each active agent administered alone.2. The method of claim 1 , wherein none of the two active agents BPO and ATRA are encapsulated.3. The method of claim 1 , wherein one of the two active agents BPO and ATRA is encapsulated either partially or entirely.4. The method of claim 1 , wherein both active agents BPO and ATRA are encapsulated either partially or entirely.5. The method of claim 1 , wherein said ...

Подробнее
17-01-2019 дата публикации

METHOD OF ACNE TREATMENT BY CONCOMITANT TOPICAL ADMINISTRATION OF BENZOYL PEROXIDE AND TRETINOIN

Номер: US20190015369A1
Принадлежит: SOL-GEL TECHNOLOGIES LTD.

The present disclosure relates to methods of treatment of acne in a patient in need thereof, comprising the concomitant once daily topical administration of from about 20 w/w to about 10% w/w of solid particulate benzoyl peroxide (BPO) and from about 0.01% w/w to about 0.1% w/w of solid particulate all trans retinoic acid (ATRA) for a period of up to 3 months, wherein the side-effects of the two actives are medically acceptable and wherein the therapeutic effect of BPO and ATRA is superior to the effect of each active administered alone. The concomitant administration may be carried out by once daily administration to a patient in need thereof of a single composition or of a first composition comprising BPO and a second composition comprising ATRA from a dual chamber dispenser or from two separate dispensers, mixed before applying on the skin of a patient in need thereof for up to 2 weeks, up to 1 month, preferably up to 2 months and more preferably up to 3 months. 1. A method of treatment of acne in a patient in need thereof , comprising the concomitant topical administration once daily for a period of up to 3 months of a stable composition , comprising from about 2% w/w to about 10% w/w of solid particulate benzoyl peroxide (BPO) and from about 0.01% w/w to about 0.1% w/w of solid particulate all trans retinoic acid (ATRA) ,wherein 90% of the solid particles of ATRA are in the range of 5-20 microns,wherein the side-effects of the two active agents BPO and ATRA are medically acceptable andwherein the therapeutic effect of BPO and ATRA is superior to the effect of each active agent administered alone.2. The method of claim 1 , wherein none of the two active agents BPO and ATRA are encapsulated.3. The method of claim 1 , wherein one of the two active agents BPO and ATRA is encapsulated either partially or entirely.4. The method of claim 1 , wherein both active agents BPO and ATRA are encapsulated either partially or entirely.5. The method of claim 1 , wherein said ...

Подробнее
17-01-2019 дата публикации

METHODS AND COMPOSITIONS FOR THE TREATMENT OF ACNE

Номер: US20190015370A1
Автор: NOV Ori, Toledano Ofer
Принадлежит: SOL-GEL TECHNOLOGIES LTD.

The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom 1. A method of treating acne comprising: topically applying onto an affected skin area of a subject in need thereof , once a day for a period of time of up to 12 weeks , a topical medicament which comprises the active agents:Tretinoin or a pharmaceutically acceptable salt thereof, in an amount of about 0.1% weight; andBenzoyl Peroxide in an amount of about 3% weight.2. The method according to claim 1 , wherein the score of at least one parameter evaluated by an investigator Cutaneous Safety Assessment is synergistically lower than the score of the parameters evaluated with the same treatment regimen with each of the active agents separately.3. The method according to claim 2 , wherein said at least one parameter evaluated by the investigator Cutaneous Safety Assessment is selected from erythema claim 2 , scaling claim 2 , pigmentation and any combinations thereof.4. The method according to claim 1 , wherein the score of at least one parameter evaluated by a Local Tolerability Score is synergistically lower than the score of the parameters evaluated with the same treatment regimen with each of the active agents separately.5. The method according to claim 4 , wherein said at least one parameter evaluated by the Local Tolerability score is selected from Itching claim 4 , Burning claim 4 , Stinging claim 4 , and any combinations thereof.6. The method according to claim 1 , wherein said topical medicament in a single dose medicament comprising both said active agents.7. The method according to claim 1 , wherein said method reduces at least one of:(i) the number of inflammatory acne lesions by at least 50%; or(ii) the number of non-inflammatory acne lesions by at least 40%.8. The method according to claim 7 , wherein said method reduces the number of non-inflammatory acne lesions by at least 40%.9. The method according to claim ...

Подробнее
15-01-2015 дата публикации

Treatment of skin disease

Номер: US20150018319A1
Принадлежит: SOLUTIONS INTERNATIONAL LLC

The present invention is drawn to compositions, systems, and methods of treating skin disease. The composition includes a peroxygen, a transition metal or alloy thereof, and optionally, an alcohol and/or a drug. The composition can be packaged as part of a two-part system, and in one example, the drug is acetylsalicylic acid.

Подробнее
16-01-2020 дата публикации

COMPOSITION AND METHOD FOR THE TOPICAL TREATMENT OF SEVERE ACNE

Номер: US20200016107A1
Автор: NACHT Sergio

The invention consists of the simultaneous use of the two stereoisomeric forms of retinoic acid with or without the addition of an antibacterial agent effective against in a cosmetically suitable topical formulation. These formulations may also contain a polymeric system that provides a gradual release of one or more of the active ingredients to obtain extended therapy with less skin irritation. 113- (canceled)14. A formulation for the topical treatment of acne containing 13-cis-retinoic acid in concentrations from 0.001% to 0.25% and another retinoid with keratolytic therapeutic action in acne in a cosmetically acceptable aqueous vehicle and containing antioxidants and preservatives suitable to protect retinoids against oxidation.15. The formulation according to claim 14 , wherein 13-cis-retinoic acid is in concentrations preferably between 0.005% to 0.15%.16. The formulation according to claim 14 , wherein the other retinoid with keratolytic therapeutic action in acne is all-trans-retinoic acid in concentrations from 0.001% to 0.25%.17. The formulation according to claim 16 , wherein the all-trans-retinoic acid is in concentrations from 0.025% to 0.10%.18P. acnes.. The formulation according to claim 14 , further comprising an antibiotic capable of controlling19P. acnes. The formulation according to claim 18 , wherein the antibiotic capable of controlling is clindamycin in concentrations of 0.5% to 3%.20. The formulation according to claim 19 , wherein the clindamycin is in concentrations between 1% and 2%.21P. acnes. The formulation according to claim 18 , wherein the antibiotic capable of controlling is erythromycin or some other tetracycline in concentrations between 1% and 5%.22. The formulation according to claim 14 , further comprising a bactericidal agent.23. The formulation according to claim 22 , wherein the bactericidal agent is benzoyl peroxide.24. The formulation according to claim 14 , wherein one or more of the active ingredients are included in ...

Подробнее
16-01-2020 дата публикации

METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS

Номер: US20200016153A1
Принадлежит:

The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α-adrenergic receptor (α-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin. 1. A method of treating facial erythema associated with rosacea in a human subject in need of such treatment , said method comprising: administering topically to the face of the human subject , a pharmaceutical composition comprising 0.001% w/w to 3% w/w of oxymetazoline hydrochloride as the sole active ingredient and a pharmaceutically acceptable carrier , wherein said pharmaceutical composition is a cream.2. The method of claim 1 , wherein said administering involves spreading the pharmaceutical composition over one or more affected areas of the face.3. The method of claim 1 , wherein said pharmaceutically acceptable carrier comprises about 50% to about 99.999% of the composition.4. The method of claim 1 , wherein the pharmaceutically acceptable carrier comprises one or more emulsifying agents.5. The method of claim 1 , wherein the pharmaceutically acceptable carrier comprises one or more oils.6. The method of claim 5 , wherein the one or more oils comprise lanolin and fatty alcohols.7. The method of claim 1 , wherein the pharmaceutically acceptable carrier comprises one or more preservatives claim 1 , solvents claim 1 , antioxidants claim 1 , emulsifying agents claim 1 , oils claim 1 , or combinations thereof.8. A method of treating erythema associated with rosacea in a human subject claim 1 , the method comprising: administering topically to an area of skin of the human subject claim 1 , a pharmaceutical cream ...

Подробнее
28-01-2016 дата публикации

Wipe for killing spores

Номер: US20160021888A1
Принадлежит: American Sterilizer Co

This invention relates to a wipe for killing spores comprising an absorbent sheet holding an aqueous composition and a sealed package containing the absorbent sheet, wherein the aqueous composition comprises water, an antimicrobial agent and a peroxide. The invention also relates to a process for killing spores using the above-indicated wipe.

Подробнее
26-01-2017 дата публикации

METHOD FOR TREATING AND/OR PREVENTING ACNE SCARS WITH A FIXED COMBINATION OF ADAPALENE OR ITS SALTS AND BENZOYL PEROXIDE

Номер: US20170020833A1
Принадлежит:

A method is described for treating and/or preventing acne scars wherein an effective amount of a composition including a fixed combination of adapalene or a salt thereof and benzoyl peroxide is administrated to a patient in need thereof. 1. A method for treating at least one acne scar , the method comprising administering an effective amount of a composition comprising a fixed combination of adapalene or a salt thereof and benzoyl peroxide to a patient in need thereof.2. The method as defined by claim 1 , wherein said composition comprises adapalene or a salt thereof in an amount ranging from 0.1% to 0.3% by weight relative to the total weight of the composition.3. The method as defined by claim 1 , wherein said composition in the form of an aqueous gel.4. The method as defined by claim 3 , wherein said at least one acne scar is an atrophic scar.5. The method as defined by claim 4 , wherein said at least one acne scar is a type of scar selected from the group consisting of ice pick claim 4 , boxcar claim 4 , rolling claim 4 , bridges and tunnels claim 4 , gross atrophy claim 4 , dystrophic and keloid scar.6. The method as defined by claim 1 , wherein said composition is topically administrated.7. The method as defined by claim 1 , wherein said composition is applied onto the scared skin.8. A method of preparing a medicament claim 1 , the method comprising formulating the medicament so that it comprises a fixed combination of adapalene and benzoyl peroxide claim 1 , wherein the medicament is further formulated for the treatment of acne scars.9. The method as defined by claim 8 , wherein the medicament is in the form of a composition suitable for topical application.10. The method as defined by claim 8 , wherein the medicament is in the form of a gel claim 8 , an emulsion claim 8 , or a lotion.11. The method as defined by claim 8 , wherein the medicament is in the form of an aqueous gel having the following composition claim 8 , as percentage by weight with respect to ...

Подробнее
10-02-2022 дата публикации

AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS

Номер: US20220040096A1
Принадлежит:

Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures. 120.-. (canceled)21. A method of treating an otic disease or condition comprising administering to an individual in need thereof a therapeutically effective amount of a composition , wherein the composition comprises an auris sensory cell modulating agent that reduces or inhibits auris sensory cell death , and about 14% to about 35% by weight of a polyoxyethylene-polyoxypropylene triblock copolymer.22. The method of claim 21 , wherein the otic disease or condition is hearing loss.23. The method of claim 21 , wherein the otic disease or condition is tinnitus.24. The method of claim 21 , wherein the auris sensory cell modulating agent that reduces or inhibits auris sensory cell death is multiparticulate.25. The method of claim 21 , wherein the pharmaceutical formulation is an auris-acceptable hydrogel.26. The method of claim 21 , wherein the pharmaceutical formulation is an auris-acceptable thermoreversible gel.27. The method of claim 26 , wherein the polyoxyethylene-polyoxypropylene triblock copolymer is Poloxamer 407.28. The method of claim 21 , wherein the composition comprises about 15% to about 25% by weight of polyoxyethylene-polyoxypropylene triblock copolymer.29. The method of claim 21 , wherein the composition comprises about 15% to about 18% by weight of polyoxyethylene-polyoxypropylene triblock copolymer.30. The method of claim 26 , further comprising a viscosity enhancer.31. The method of claim 30 , wherein the viscosity enhance is alginate.32. The ...

Подробнее
24-01-2019 дата публикации

COMPOSITIONS COMPRISING PEROXYACID AND METHODS FOR PRODUCING AND USING THE SAME

Номер: US20190021330A1
Принадлежит: Armis Biopharma, Inc.

The present invention provides methods for producing a non α-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods, and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound. In particular, compositions of the invention provide for a mixture of an α-keto peracid and a non α-keto peracid that works synergistically to reduce microbes on a surface, to prevent vegetative bacteria on a surface and to heal a wound in animals or humans. 1. A composition comprising the products of a method comprising: contacting at least one first α-keto carboxylic acid with an oxidizing agent to form a mixture , and stirring the mixture at a temperature from −20° C. to 0° C.2. The composition of further comprising a gel claim 1 , a lotion claim 1 , or an irrigation gel.3. The composition of further comprising a liquid claim 1 , a spray claim 1 , or application granules.4. The composition of claim 1 , wherein the oxidizing agent is at least one agent selected from the group consisting of hydrogen peroxide claim 1 , barium peroxide claim 1 , sodium carbonate peroxide claim 1 , calcium peroxide claim 1 , sodium perborate claim 1 , lithium peroxide claim 1 , magnesium peroxide claim 1 , strontium peroxide claim 1 , zinc peroxide claim 1 , potassium superoxide.5. The composition of claim 4 , wherein the oxidizing agent is hydrogen peroxide.6. The method of claim 1 , wherein the at least one first α-keto carboxylic acid is selected such that the at least one first peroxycarboxylic acid is selected from the group consisting of peroxypentanoic acid claim 1 , peroxyhexanoic acid claim 1 , peroxyheptanoic acid claim 1 , peroxyoctanoic acid claim 1 , peroxynonanoic acid claim 1 , peroxydecanoic acid claim 1 , peroxyundecanoic acid claim 1 , peroxydodecanoic acid claim 1 , the peroxyacids of the branched ...

Подробнее
10-02-2022 дата публикации

COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, MILD HYPEROPIA, AND IRREGULAR ASTIGMATISM

Номер: US20220040152A1
Автор: Abad Juan Carlos
Принадлежит:

The present invention is directed to compositions and methods for treating ocular conditions, including presbyopia, mild hyperopia, irregular astigmatism, hyperopic accommodative esotropia, and glaucoma. The compositions can also be used to potentiate or enhance interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor Magonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity. It has been found that an alpha agonist having an imidazoline group or non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity in combination with a cholinergic agent, such as pilocarpine, act synergistically to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound. 131-. (canceled)33. The composition of claim 32 , wherein the composition further comprises an ophthalmically acceptable carrier.34. The composition of claim 32 , wherein the composition further comprises a cyclodextrin or derivative thereof to enhance ocular penetration of the composition.35. The composition of claim 32 , wherein the composition is in the form of an eye drop claim 32 , suspension claim 32 , gel claim 32 , ointment claim 32 , injectable solution claim 32 , or spray.36. The composition of claim 32 , wherein the NSAID is meloxicam.37. The composition of claim 32 , wherein the NSAID is celecoxib.38. The composition of claim 32 , wherein the NSAID is rofecoxib.39. The composition of claim 32 , wherein the NSAID is valdecoxib.40. The composition of claim 32 , wherein the NSAID is parecoxib.41. The composition of claim 32 , wherein the NSAID is etoricoxib.42. The composition of claim 32 , wherein the NSAID is nimesulide.43. The composition of claim 32 , wherein the NSAID is etodolac.44. The composition of claim 32 , wherein the ...

Подробнее
24-01-2019 дата публикации

HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY

Номер: US20190022049A1
Принадлежит:

Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, 2. The compounds claim 1 , the salts claim 1 , the hydrates or the solvates according to claim 1 , wherein: the substituent groups in R are halogen claim 1 , amino group claim 1 , nitro group claim 1 , ester group claim 1 , carbonyl group claim 1 , amino acid derivatives claim 1 , natural flavone claim 1 , natural alkaloid claim 1 , polyethylene glycol claim 1 , polyglutamic acid or polysaccharide.3. The compounds claim 1 , the salts claim 1 , the hydrates or the solvates according to claim 1 , wherein:{'sub': '2', 'when X is C═O, Y is NH; when X is CH, Y is O; or'}{'sub': '2', 'X is C═O or CH, Y is absent.'}4. The compounds claim 3 , the salts claim 3 , the hydrates or the solvates according to claim 3 , wherein: the compound is:1) (2-tert-butyl-4-methoxyphenol) (N-benzyl)carbamate,2) (2-tert-butyl-4-methoxyphenol) (N-n-butyl)carbamate,3) (2-tert-butyl-4-methoxyphenol) (N-isopropyl)carbamate,4) (2-tert-butyl-4-methoxyphenol) (N-cyclohexyl)carbamate,5) (2-tert-butyl-4-methoxyphenol) (N-phenethyl)carbamate,6) pivaloyl(2-tert-butyl-4-methoxyphenol-oxyl) methyl ester,7) 2-tert-butyl-4-methoxyphenol benzoate,8) 2-tert-butyl-4-methoxyphenol acetate,9) 2-tert-butyl-4-methoxyphenol nicotinate,10) 2-tert-butyl-4-methoxyphenol isonicotinate,11) 2-tert-butyl-4-methoxyphenol cyclohexenecarboxylate,12) 2-tert-butyl-4-methoxyphenol propionate,13) 2-tert-butyl-4-methoxyphenol acrylate,14) (2-tert-butyl-4-methoxyphenol) 3,4-dimethoxyphenylacetate,15) 2-tert-butyl-4-methoxyphenol butynoate,16) bis(2-tert-butyl-4-methoxyphenol) 2,2′-biphenyldicarboxylate,17) (2-tert-butyl-4-methoxyphenol) 2-chloro-5-trifluoromethylbenzoate,18) (2-tert-butyl-4-methoxyphenol) 3-fluorophenylacetate,19) (2-tert-butyl-4-methoxyphenol) (1H-indole-3-yl)acetate,20) (2-tert-butyl-4-methoxyphenol) 3-(4-fluorophenyl ...

Подробнее
24-01-2019 дата публикации

FORMULATION FOR THE TREATMENT OF ACNE

Номер: US20190022050A1
Принадлежит:

Peroxide of the formula wherein Ris selected from linear and branched alkyl groups with 1-4 carbon atoms, and R, R, and Rare selected from hydrogen and linear and branched alkyl groups with 1-4 carbon atoms, for use as a medicament, in particular for the treatment of acne. 2. (canceled)3. The method of wherein Rand Rare selected from methyl claim 1 , tert-butyl claim 1 , and n-butyl groups.4. The method of wherein Rand Rare both hydrogen.5. The method of wherein Rand Rare positioned at the para position.6. The method of wherein the peroxide is di(4-methylbenzoyl)peroxide.8. The method of wherein the peroxide is di(4-methylbenzoyl)peroxide.10. Skin-treatment formulation according to wherein the peroxide is di(4-methylbenzoyl)peroxide.11. Skin-treatment formulation according to wherein the peroxide is present in the formulation in a concentration of 0.1-20 wt %.12. Skin-treatment formulation according to wherein the dispersant system contains one or more compounds selected from suspending agent(s) claim 9 , gelling aid(s) claim 9 , buffering agent(s) claim 9 , defoamer(s) claim 9 , and dispersant(s).14. The method according to wherein the peroxide is di(4-methylbenzoyl)peroxide. The present invention relates to an organic peroxide for the treatment of acne and a skin treatment formulation comprising this organic peroxide.Acne vulgaris is a chronic disorder of the pilosebaceous follicles (apparati) which is characterized by comedones (blackheads), papules, pustules, cysts, nodules and often scars which appear in the most visible regions of the skin, in particular the face, chest, back and sometimes the neck and top of the arms. Acne affects 90% of all adolescents and many men and women of older age.Acne is caused by bacteria, such as (ATCC 6538), (ATCC 12228), and (ATCC 6919).Dibenzoyl peroxide is a well-known active ingredient in formulations for the treatment of acne. It is able to inhibit the proliferation of the above-mentioned bacteria.Surprisingly, it has now ...

Подробнее
24-01-2019 дата публикации

BIOPHOTONIC COMPOSITIONS FOR THE TREATMENT OF PYODERMA

Номер: US20190022218A1
Принадлежит: KLOX TECHNOLOGIES LIMITED

The present document describes methods and uses of biophotonic compositions which comprise at least one oxidant and at least one chromophore capable of activating the oxidant, in association with a pharmacologically acceptable carrier for the treatment of pyoderma, deep pyoderma, or antibiotic resistant pyoderma. 1. A method of treating pyoderma , deep pyoderma , or antibiotic-resistant pyoderma comprising:a) applying a biophotonic composition to a patient in need thereof, wherein the biophotonic composition comprises at least one oxidant and at least one chromophore capable of activating the oxidant; andb) exposing said biophotonic composition to actinic light for a time sufficient for said chromophore to cause activation of said oxidant.2. The method according to claim 1 , wherein the patient is a mammal.3. The method according to claim 2 , wherein the mammal is a canine.4. The method according to claim 2 , wherein the mammal is a feline.5. The method according to any one of to claim 2 , wherein the composition is applied to the patient's skin.6. The method according to any one of to claim 2 , wherein said biophotonic composition is exposed to actinic light for a period of less than about 5 minutes.7. The method according to any one of to claim 2 , wherein said biophotonic composition is exposed to actinic light for a period of from about 1 second to about 5 minutes.8. The method according to any one of to claim 2 , wherein said biophotonic composition is exposed to actinic light for a period of less than about 5 minutes per cmof an area to be treated.9. The method according to any one of to claim 2 , wherein said biophotonic composition is exposed to actinic light for a period of about 1 second to about 5 minutes per cmof an area to be treated.10. The method according to any one of to claim 2 , wherein the source of actinic light is positioned over an area to be treated.11. The method according to any one of to claim 2 , wherein said actinic light is visible ...

Подробнее
24-01-2019 дата публикации

BIOPHOTONIC COMPOSITIONS FOR TREATING SKIN AND SOFT TISSUE WOUNDS HAVING EITHER OR BOTH NON-RESISTANT AND RESISTANT INFECTIONS

Номер: US20190022219A1
Принадлежит:

The present document describes methods and uses of biophotonic compositions which comprise at least one oxidant and at least one chromophore capable of activating the oxidant, in association with a pharmacologically acceptable carrier for use in the treatment of skin and soft tissue wounds that have either or both non-resistant and resistant infections. 1. A method of treating a skin or soft tissue wound having a non-resistant or a resistant infection , or both categories of infection , comprising:a) applying a biophotonic composition to a patient in need thereof, wherein the biophotonic composition comprises at least one oxidant and at least one chromophore capable of activating the oxidant; andb) exposing said biophotonic composition to actinic light for a time sufficient for said chromophore to cause activation of said oxidant.2. The method according to claim 1 , wherein the infection is a bacterial infection.3. The method according to claim 2 , wherein the bacterial infection is resistant to antibiotics.48.-. (canceled)94. The method according to claim claim 2 , wherein the infection is an antibiotic resistant infection.10. The method according to claim 1 , wherein the wound is a skin wound.11. The method according to claim 1 , wherein the method promotes the healing of wound.12. The method according to claim 1 , wherein the soft tissue wound comprises an oral disease.13. The method according to claim 1 , wherein said biophotonic composition is exposed to actinic light for a period of less than about 5 minutes.1416.-. (canceled)17. The method according to claim 1 , wherein the source of actinic light is positioned over an area to be treated.18. The method according to claim 1 , wherein said actinic light is visible light having a peak wavelength from about 400 nm to about 700 nm.19. The method according to claim 1 , wherein the oxidant is chosen from hydrogen peroxide claim 1 , carbamide peroxide and benzoyl peroxide.20. (canceled)21. The method according to ...

Подробнее
28-01-2021 дата публикации

Functionalized Pyridine Carbamates with Enhanced Neuroprotective Activity

Номер: US20210023064A1
Принадлежит:

The present invention includes compositions and methods for treating a subject afflicted with a neurodegenerative disorder or disease by determining that the subject is in need of treatment for the neurodegenerative disorder or disease; and administering to the subject an amount of an effective amount of a compound comprising a flupirtine derivative as disclosed herein. 2. The method of claim 1 , wherein the amount of the compound is effective to reduce a symptom of the neurodegenerative disorder or disease in the subject.3. The method of claim 1 , wherein the neurodegenerative disorder or disease is a brain atrophy claim 1 , neuronal dysfunction claim 1 , neuronal injury claim 1 , neuronal degeneration claim 1 , neuronal apoptosis claim 1 , risk for confirmed progression claim 1 , deterioration of visual function claim 1 , fatigue claim 1 , impaired mobility claim 1 , cognitive impairment claim 1 , or reduction of brain volume.4. The method of claim 1 , wherein the amount of compound is effective to reduce cognitive impairment.5. The method of claim 1 , further comprising adapting the composition for oral claim 1 , intravenous claim 1 , cutaneous claim 1 , peritoneal claim 1 , parenteral claim 1 , rectal claim 1 , pulmonary claim 1 , nasal claim 1 , administration.6. The method of claim 1 , further comprising adapting the composition for slow release form or an immediate release form.7. The method of claim 1 , further comprising combining the composition with a pharmaceutically acceptable excipient.8. The method of claim 1 , further comprising combining the composition with the pharmaceutically acceptable excipient that is selected from at least one of lactose claim 1 , lactose monohydrate claim 1 , starch claim 1 , isomaltose claim 1 , mannitol claim 1 , sodium starch glycolate claim 1 , sorbitol claim 1 , lactose spray dried claim 1 , lactose anhydrous claim 1 , or a combination thereof.9. The method of claim 1 , further comprising adapting the composition for ...

Подробнее
24-01-2019 дата публикации

Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity

Номер: US20190024084A1
Принадлежит: Curna Inc

The present invention relates to antisense oligonucleotides and/or compounds that modulate the expression of and/or function of Filaggrin (FLG), in particular, by targeting natural antisense polynucleotides of Filaggrin (FLG). The invention also relates to the identification of these antisense oligonucleotides and/or compounds and their use in treating diseases and disorders associated with the expression of FLG.

Подробнее
04-02-2016 дата публикации

Phenyl Carbamate Compounds for Use in Preventing or Treating Epilepsy or Epilepsy-Related Syndrome

Номер: US20160030382A1
Автор: Choi Yong Moon
Принадлежит:

The present invention provides a pharmaceutical composition for preventing and/or treating a epilepsy or epilepsy-related syndrome, for example an intractable epilepsy or its related syndrome such as drug-resistant epilepsy, comprising the phenyl carbamate compound as an active ingredient, and a use of the phenyl carbamate compound for preventing and/or treating epilepsy or epilepsy-related syndrome. 2. The pharmaceutical composition according to claim 1 , wherein A is hydrogen and B is carbamoyl group claim 1 , or A is a carbamoyl group and B is hydrogen.3. The pharmaceutical composition according to claim 1 , wherein the phenyl carbamate compound is in the form of racemate claim 1 , enantiomer claim 1 , diastereomer claim 1 , a mixture of enantiomer claim 1 , or a mixture of diastereomer.4. The pharmaceutical composition according to claim 1 , wherein X is chlorine claim 1 , fluorine claim 1 , iodine claim 1 , or bromine; n is 1 or 2; and R2 and R3 are the same as or different from each other claim 1 , and independently selected from the group consisting of hydrogen claim 1 , methyl group claim 1 , propyl group claim 1 , isopropyl group claim 1 , cyclopropyl group claim 1 , cyclohexyl group claim 1 , bicycloheptane group claim 1 , and benzyl group.5. The pharmaceutical composition according to claim 1 , wherein the phenyl carbamate compound is selected from the group consisting of:1-(2-chlorophenyl)-1-hydroxypropyl-2-carbamate,1-(2-chlorophenyl)-1-hydroxy-3-methyl-butyl-2-carbamate,1-(2-chlorophenyl)-1-hydroxyhexyl-2-carbamate,1-(2-chlorophenyl)-1-hydroxypropyl-2-N-methylcarbamate,1-(2-chlorophenyl)-1-hydroxypropyl-2-N-propylcarbamate,1-(2-chlorophenyl)-1-hydroxypropyl-2-N-isopropylcarbamate,1-(2-chlorophenyl)-1-hydroxypropyl-2-N-cyclopropylcarbamate,1-(2-chlorophenyl)-1-hydroxypropyl-2-N-cyclohexylcarbamate,1-(2-chlorophenyl)-1-hydroxypropyl-2-N-benzylcarbamate,1-(2-chlorophenyl)-1-hydroxypropyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2,4-dichlorophenyl)-1- ...

Подробнее
24-04-2014 дата публикации

Compositions Comprising Peroxyacid and Methods for Producing and Using the Same

Номер: US20140113000A1
Принадлежит: CHD BIOSCIENCE, INC.

The present invention provides methods for producing a non α-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound. In particular, compositions of the invention provide for a mixture of an α-keto peracid and a non α-keto peracid that works synergistically to reduce microbes on a surface, to prevent vegetative bacteria on a surface and to heal a wound in animals or humans. 1. A method for producing a composition comprising a non α-keto peracid and an α-keto peracid , the method comprising:contacting an α-keto carboxylic acid with an oxidizing agent under conditions sufficient to produce the α-keto peracid; andcontacting an α-keto carboxylic acid with an oxidizing agent under conditions sufficient to produce the non α-keto peracid.2. The method of claim 1 , wherein the oxidizing agent is selected from the group consisting of hydrogen peroxide claim 1 , barium peroxide claim 1 , sodium carbonate peroxide claim 1 , calcium peroxide claim 1 , sodium perborate claim 1 , lithium peroxide claim 1 , magnesium peroxide claim 1 , strontium peroxide claim 1 , zinc peroxide claim 1 , potassium superoxide claim 1 , or a mixture thereof.3. The method of claim 1 , wherein the reaction temperature ranges from about −30° C. to about 10° C.4. The method of claim 1 , wherein the α-keto carboxylic acid comprises an α-keto monocarboxylic acid.5. The method of claim 1 , wherein the α-keto carboxylic acid comprises an α-keto dicarboxylic acid.6. The method of claim 1 , wherein the α-keto carboxylic acid is selected from the group consisting of pyruvic acid claim 1 , α-keto butyric acid claim 1 , α-keto valeric acid claim 1 , α-keto glutaric acid. 2-oxo cylopental acetic acid claim 1 , or a mixture thereof.7. The method of claim 1 , wherein ...

Подробнее
29-01-2015 дата публикации

COMPOSITIONS AND METHODS FOR TREATING UNDERACTIVE BLADDER

Номер: US20150030667A1
Принадлежит: LIPELLA PHARMACEUTICALS, INC.

Methods and compositions for treating underactive bladder and/or symptoms thereof are disclosed, wherein the composition including an effective amount of a therapeutic agent and a pharmaceutically acceptable lipid vehicle is locally administered to the bladder, thereby treating the underactive bladder and/or symptoms thereof. 1. A method for treating an underactive bladder condition or symptoms thereof comprising: locally administering to the bladder a composition comprising a pharmaceutically acceptable lipid vehicle and an effective amount of a therapeutic agent , wherein the underactive bladder condition or symptoms thereof are treated.2. The method of claim 1 , wherein the underactive bladder condition or symptoms thereof is selected from urinary retention claim 1 , incomplete bladder emptying claim 1 , slow or intermittent stream claim 1 , hesitancy claim 1 , terminal dribbling claim 1 , straining to urinate that is related to diabetes claim 1 , neurological diseases affecting the nerves to and from the bladder claim 1 , bladder outlet obstruction and impaired contractility of detrusor muscle and combinations thereof.3. The method of claim 1 , wherein the underactive bladder condition or symptoms thereof is caused by a condition selected from benign prostate hyperplasia claim 1 , urethral stricture claim 1 , paruresis claim 1 , detrusor muscle underactivity claim 1 , underactive bladder syndrome claim 1 , anticholinergic drug effect claim 1 , bladder sensory dysfunction claim 1 , diabetes and combinations thereof.4. The method of claim 1 , wherein the effective amount of the therapeutic agent is an amount less than the amount administered systemically to obtain the same therapeutic efficacy.5. The method of claim 1 , wherein the local administration is selected from instillation claim 1 , drug eluting matrix claim 1 , drug eluting device claim 1 , topical and combinations thereof.6. The method of claim 1 , wherein the composition further comprises a ...

Подробнее
24-04-2014 дата публикации

Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism

Номер: US20140113946A1
Автор: Juan Carlos Abad
Принадлежит: Allergan Inc

The present invention is directed to compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M 3 agonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity. It has been found that an alpha agonist having an imidazoline group or non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity in combination with a cholinergic agent, such as pilocarpine, act synergistically to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound.

Подробнее
02-02-2017 дата публикации

INHIBITORS OF HISTONE LYSINE SPECIFIC DEMETHYLASE (LSD1) AND HISTONE DEACETYLASES (HDACS)

Номер: US20170029366A1
Принадлежит:

A series of phenelzine analogs comprising a phenelzine scaffold linked to an aromatic moiety and their use as inhibitors of lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) is provided. The presently disclosed phenelzine analogs exhibit potency and selectivity for LSD1 versus MAO and LSD2 enzymes and exhibit bulk, as well as, gene specific histone methylation changes, anti-proliferative activity in several cancer cell lines, and neuroprotection in response to oxidative stress. Accordingly, the presently disclosed phenelzine analogs can be used to treat diseases, conditions, or disorders related to LSD1 and/or HDACs, including, but not limited to, cancers and neurodegenerative diseases. 13. A pharmaceutical composition comprising a compound of Formula (I) or Formula (II).14. The pharmaceutical composition of claim 13 , further comprising one or more additional therapeutic agents.15. The pharmaceutical composition of claim 14 , wherein the one or more additional therapeutic agents is selected from the group consisting of a histone deacetylase (HDAC) inhibitor claim 14 , a DNA methyltransferase (DNMT) inhibitor claim 14 , and combinations thereof.16. A method for inhibiting lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) claim 14 , the method comprising administering to a subject a compound of Formula (Ia) or a compound of Formula (II) claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , in an amount effective to inhibit LSD1 or one or more HDACs.17. A method for treating a disease claim 14 , disorder claim 14 , or condition associated with lysine-specific demethylase 1 (LSD1) and/or one or more histone deacetylases (HDACs) claim 14 , the method comprising administering to a subject in need of treatment thereof subject a compound of Formula (Ia) or Formula (II) claim 14 , or a pharmaceutically acceptable salt thereof claim 14 , in an amount effective to inhibit LSD1 and/or one or ...

Подробнее
31-01-2019 дата публикации

INGENOL ANALOGS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Номер: US20190030029A1
Принадлежит:

The invention relates to compounds of Formula (I), (II), (III) or (IV), salts thereof, pharmaceutical compositions thereof, as well as methods of treating, curing or preventing HIV in subjects. 15-. (canceled)7. The compound according to claim 6 , wherein Ris present and selected from the group consisting of —H and —C(O)R.8. The compound according to claim 7 , wherein Ris H.9. The compound according to claim 7 , wherein Ris —C(O)Rand Ris —N((R)(R).10. The compound according to claim 9 , wherein Ris methyl and Ris aryl substituted by chloro.11. The compound according to claim 6 , wherein X is O.12. The compound according to claim 11 , wherein Ris —C(O)R.13. The compound according to claim 12 , wherein Ris aryl or methyl.14. The compound according to claim 6 , wherein X is N.15. The compound according to claim 14 , wherein Rand Rtogether form a (C-C) heteroaryl.16. The compound according claim 6 , wherein Ris absent.17. The compound according to claim 16 , wherein X is O and Ris H.18. The compound according to claim 6 , wherein{'sup': '2', 'X is O and Ris'}{'sup': 6a', '6b, '—C(O)N(R)(R).'}19. The compound according to claim 18 , wherein Rand Rare selected from the group consisting of H claim 18 , (C-C)alkyl claim 18 , (C-C)aryl claim 18 , (C-C)heteroaryl claim 18 , (C-C) cycloalkyl claim 18 , (C-C)heterocycle and (C-C)alkyl-Rwherein Rmay be (C-C)aryl claim 18 , (C-C)heteroaryl claim 18 , (C-C) cycloalkyl or (C-C)heterocycle or wherein when Ror Ris —C(O)N(R)(R) claim 18 , Rand Rmay together form a (C-C) heteroaryl or a (C-C) heterocycle.20. The compound according to claim 19 , wherein Rand Rare selected from the group consisting of H claim 19 , (C)alkyl claim 19 , (C)aryl claim 19 , (C)alkyl-Rwherein Ris (C-C)aryl and (C) cycloalkyl.21. The compound according to claim 19 , wherein Rand Rtogether form a (C-C) heteroaryl or a (C-C) heterocycle.22. The compound according to claim 21 , wherein Rand Rtogether form a (C) heteroaryl.23. The compound according to claim 6 , ...

Подробнее
30-01-2020 дата публикации

METHOD AND COMPOSITION FOR SURGERY PREPAREDNESS AND RECOVERY

Номер: US20200030273A1
Принадлежит:

The present invention relates to compositions and methods to increase nitric oxide production to: accelerate wound healing, reduce complications from surgery as well as accelerating the recovery period after surgery. The compositions comprise of l-arginine and l-citrulline in ratios and dosages which enable enhanced bioavailability. The method for using the composition for promoting surgery recovery and preparedness includes the step of administering the composition to a patient pre-procedure as well as post-procedure in accordance with a prescribed protocol. The compositions may be customized to include one or more additional agents that are effective for promoting nutritional health and/or treating a particular medical problem. 1. A micronutrient composition to enhance nitric oxide production administered in a unit dose wherein said unit dose comprises:a. The amino-acids l-arginine and l-citrulline in mass ratios between about 0.3 and 3.0 (l-arginine/l-citrulline) with a combined total mass of between about 1 g and 20 g.2. A composition of claim 1 , wherein said unit dose further includes one or more antioxidant(s) claim 1 , amino acid(s) and/or proteolytic or hemolytic enzyme(s). This includes claim 1 , but is not limited to: vitamin C claim 1 , glutamine claim 1 , and bromelain.3. A method to reduce complications associated with a surgical procedure comprising the step of orally administering a unit dose of the composition of and/or to the patient beginning at least 2 days prior to a surgical procedure and at least 3 days after. This patent claims the benefit of U.S. Provisional Application No. 62/539,748 filed Aug. 1, 2017.The present invention relates to compositions and a method to accelerate wound healing and reduce complications and accelerate recovery associated with a surgical procedure.Wound healing is generally recognized to occur in three phases with different cell types performing different functions. These phases are generally divided into the ...

Подробнее
04-02-2021 дата публикации

TOPICAL COMPOSITIONS

Номер: US20210030778A1
Принадлежит:

The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same. 1. A topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate , 2.5-3.5 wt. % benzoyl peroxide , and 0.1-0.2 wt. % adapalene , in combination with a gelling agent , a polyhydric alcohol , and water.2. The formulation of wherein the formulation comprises about 1.2 wt. % clindamycin phosphate claim 1 , about 3.1 wt. % benzoyl peroxide claim 1 , and about 0.15 wt. % adapalene.3. The formulation of wherein the formulation comprisesa. about 1.2 wt. % clindamycin phosphate,b. about 3.1 wt. % benzoyl peroxide,c. about 0.15 wt. % adapalene,d. about 5 wt. % propylene glycol,e. about 1.75 wt. % carbomer homopolymer Type C,f. potassium hydroxide in an amount to provide a pH of 5-6, andg. water.4. A method of treating an inflammatory skin condition in a patient in need thereof claim 1 , comprising administering to the affected area on at least a daily basis claim 1 , a topical gel formulation according to .5. The method of wherein the inflammatory skin condition is acne.6. The method of wherein administration is once daily over a period of at least 4 weeks.7. The method of wherein the treatment is more effective in treating acne than treatment with a formulation comprising active ingredients selected from (i) 1-1.5 wt. % clindamycin phosphate and 2.5-3.5 wt. % benzoyl peroxide claim 6 , (ii) 2.5-3.5 wt. % benzoyl peroxide and 0.1-0.2 wt. % adapalene claim 6 , and (iii) 1-1.5 wt. % clindamycin phosphate and 0.1-0.2 wt. % adapalene.8. A drug product which is a container claim 1 , comprising a pump and containing a topical gel formulation according to claim 1 , wherein the pump is calibrated to release a specific amount of the ...

Подробнее
05-02-2015 дата публикации

Treatment of macrophage-related disorders

Номер: US20150037320A1

The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.

Подробнее
05-02-2015 дата публикации

Methods of use comprising a biocidal polyamine

Номер: US20150038705A1

Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, reduce biofilms, and/or inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.

Подробнее
09-02-2017 дата публикации

Compositions and Methods for the Treatment of Meibomian Gland Dysfunction

Номер: US20170035785A1
Принадлежит:

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction. 130.-. (canceled)31. A method for treating meibomian gland dysfunction in a patient in need thereof , comprising topically administering to the patient a composition that reaches the eyelid margin of the patient , wherein the composition comprises a therapeutically-effective amount of at least one keratolytic agent in an ophthalmically-acceptable carrier , wherein the keratolytic agent is benzoyl peroxide or salicylic acid.32. The method of claim 31 , wherein the keratolytic agent is benzoyl peroxide.33. The method of claim 32 , wherein the concentration of the benzoyl peroxide in the composition is about 2.5% claim 32 , about 5% claim 32 , or about 10%34. The method of claim 31 , wherein the keratolytic agent is salicylic acid.35. The method of claim 34 , wherein the concentration of the salicylic acid in the composition is between about 0.1% to about 30%.36. The method of claim 34 , wherein the concentration of the salicylic acid in the composition is between about 0.1% to about 10%.37. The method of claim 34 , wherein the concentration of the salicylic acid in the composition is between about 0.1% to about 6%.38. The method of claim 31 , wherein composition is topically administered to the patient until the keratinized obstruction is relieved.39. The method of claim 31 , wherein composition is topically administered to the patient periodically after relieving the keratinized obstruction.40. The method of claim 31 , wherein the topical administration is a single administration.41. The method of claim 31 , wherein the topical administration is a periodic administration.42. The method of ...

Подробнее
07-02-2019 дата публикации

NUTRITIONAL COMPOSITION

Номер: US20190038687A1
Автор: Hsia Houn Simon
Принадлежит:

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals. 1. An orally administrable nutritional composition comprising:selenium yeast;0.5 mg to 1.5 g fish oil, the fish oil having a combined EPA/DHA content of between 10% to 90% and an EPA/DHA ratio of between 1:5 and 5:1; and500 iu to 10,000 iu beta carotene;a milk protein;a rice protein; andinositol,wherein components of the nutritional composition are provided in amounts effective to both reduce cachectic symptoms and suppress neoplastic growth in the cancer patient when provided in combination.2. The nutritional composition of claim 1 , wherein the selenium yeast is in an amount from 10 μg to 250 μg.3. The nutritional composition of claim 1 , wherein the selenium yeast is in an amount from 25 μg to 1500 μg.4Saccharomyces cerevisiae, Saccharomyces exiguous, Saccharomyces pastorianus, Saccharomyces boulardii, Saccharomyces bayanus, Saccharomyces eubayanus, Saccharomyces florentinusSaccharomyces fragilis.. The nutritional composition of claim 1 , wherein the selenium yeast is one or more of the group consisting of: claim 1 , and5. The nutritional composition of claim 1 , wherein the fish oil has an EPA/DHA content of between 30% to 70%.6. The nutritional composition of claim 1 , wherein the fish oil has an EPA/DHA content of between 40% to 60%.7. The nutritional composition of claim 1 , wherein the fish oil has an EPA/DHA ratio of about 2:1.8. The nutritional composition of claim 1 , wherein the fish oil has an EPA/DHA ratio of about 3:2.9. The ...

Подробнее
15-02-2018 дата публикации

Methods and compositions for treatment of epileptic disorders

Номер: US20180042903A1
Автор: Matthew During
Принадлежит: Ovid Therapeutics Inc

Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.

Подробнее
13-02-2020 дата публикации

AMINOCARBONYLCARBAMATE COMPOUNDS

Номер: US20200046674A1
Принадлежит:

The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: 2. The method of claim 1 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.3. The method of claim 1 , wherein the compound is administered with at least one pharmaceutically-acceptable carrier.4. The method of claim 3 , wherein the carrier is lactose claim 3 , dibasic calcium phosphate claim 3 , corn starch or a mixture thereof.5. The method of claim 1 , wherein the compound is administered orally.6. The method of claim 1 , further comprising one or more additional therapeutic agents.7. The method of claim 6 , wherein the one or more additional therapeutic agents are independently selected from the group consisting of amphetamine claim 6 , methylphenidate claim 6 , dextroamphetamine claim 6 , dexmethylphenidate claim 6 , and lisdexamfetamine.9. The method according to claim 8 , wherein the compound is selected from the group consisting of:2-(isopropylamino)-3-phenylpropyl (aminocarbonyl)carbamate;2-(dimethylamino)-3-phenylpropyl (aminocarbonyl)carbamate;2-(methylamino)-3-phenylpropyl (aminocarbonyl)carbamate; and2-amino-3-phenylpropyl (anilinocarbonyl)carbamate.10. The method according to claim 8 , wherein the compound is selected from the group consisting of:(2R)-2-(isopropylamino)-3-phenylpropyl (aminocarbonyl)carbamate;(2R)-2-(dimethylamino)-3-phenylpropyl (aminocarbonyl)carbamate;(2R)-2-(methylamino)-3-phenylpropyl (aminocarbonyl)carbamate; and(2R)-2-amino-3-phenylpropyl (anilinocarbonyl)carbamate.11. The method according to claim 8 , wherein the salt is hydrochloride.13. The method according to claim 12 , wherein the compound is selected from the group consisting of:2-amino-3-phenylpropyl (aminocarbonyl)methyl carbamate;2-(dimethylamino)-3-phenylpropyl (aminocarbonyl)methylcarbamate;2-amino-3-phenylpropyl (aminocarbonyl)benzylcarbamate;2-amino-3- ...

Подробнее
22-02-2018 дата публикации

A SYNERGISTIC INSECTICIDAL COMPOSITION

Номер: US20180049439A1
Автор: BRISTOW James Timothy

A synergistic insecticidal composition comprising two components: (A) at least one carbamate insecticide and (B) at least one pyrethroid insecticide is provided. There is also provided a process for preparing the insecticidal composition. A method to prevent, control and/or treat insect infestations in plants, plant parts and/or their surroundings by applying the synergistic insecticidal composition comprising the two components (A) and (B) is also provided. 1. An insecticidal composition comprising at least one carbamate insecticide and at least one pyrethroid insecticide.2. The composition according to claim 1 , wherein the carbamate insecticide is selected from methiocarb claim 1 , methomyl claim 1 , oxamyl claim 1 , pirimicarb and thiodicarb.3. The composition according to claim 2 , wherein the carbamate insecticide is methomyl.4. The composition according to claim 1 , wherein the pyrethroid insecticide is selected from cypermethrin claim 1 , bifenthrin claim 1 , esfenvalerate claim 1 , etofenprox and tefluthrin.5. The composition according to claim 4 , wherein the pyrethroid insecticide is bifenthrin.6. The composition according to claim 1 , wherein the carbamate insecticide is present in an amount of from 1 to 75% by weight of the composition claim 1 , and/or the pyrethroid insecticide is present in an amount of from 1 to 50% by weight.7. The composition according to claim 1 , wherein the ratio of the carbamate insecticide to the pyrethroid insecticide is from 99:1 to 1:99.8. The composition according to claim 7 , wherein the ratio is from 1:12 to 12:1.9. The composition according to further comprising one or more auxiliaries selected from extenders claim 1 , carriers claim 1 , solvents claim 1 , surfactants claim 1 , stabilizers claim 1 , anti-foaming agents claim 1 , anti-freezing agents claim 1 , preservatives claim 1 , antioxidants claim 1 , colorants claim 1 , thickeners claim 1 , solid adherents and inert fillers.10. Use of a composition of for ...

Подробнее
22-02-2018 дата публикации

METHODS AND COMPOSITIONS FOR THE TREATMENT OF WARTS

Номер: US20180050009A1
Принадлежит:

Embodiments are directed to compositions comprising greater than 40% w/w to about 70% w/w stabilized hydrogen peroxide. The composition may also include a surface tension modifying agent, such as 2-propanol. Such compositions may be used to treat conditions such as warts, condyloma accuminatum, molluscum contagiosum, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions. 1. A method of treating warts or a wart associated condition in a subject in need thereof comprising administering to the subject a topical composition comprising greater than 40% w/w to about 70% w/w hydrogen peroxide.2. The method of claim 1 , wherein the topical composition comprises hydrogen peroxide in an amount of about 45% w/w claim 1 , about 50% w/w claim 1 , about 54% w/w claim 1 , about 55% w/w claim 1 , about 59% w/w claim 1 , or a range of any two of these values.3. The method of claim 1 , wherein the topical composition further comprises greater than 0% w/w to about 15% w/w 2-propanol.4. The method of claim 1 , wherein the topical composition further comprises greater than 0% w/w to about 5% w/w 2-propanol.5acuminata. The method of claim 1 , wherein the warts or the wart associated condition is selected from the group consisting of common warts claim 1 , filiform warts claim 1 , genital warts claim 1 , external genital warts claim 1 , condyloma claim 1 , recurrent warts claim 1 , persistent warts claim 1 , periungual warts claim 1 , subungual warts claim 1 , plantar warts claim 1 , mosaic warts claim 1 , recalcitrant warts claim 1 , treatment naïve warts claim 1 , palmoplantar warts claim 1 , flat warts claim 1 , epidermodysplasia verruciformis related warts claim 1 , butcher's warts claim 1 , oropharyngeal warts claim 1 , laryngeal warts claim 1 , laryngeal papillomas claim 1 , laryngeal dysplasias claim 1 , anogenital warts claim 1 , cervical dysplasia claim 1 , ...

Подробнее
15-05-2014 дата публикации

TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT

Номер: US20140134252A1
Автор: Chang Yunik, Dow Gordon J.
Принадлежит: Dow Pharmaceutical Sciences, Inc.

An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. 1. A surfactant-free , aqueous 2.5% w/w benzoyl peroxide gel formulation for topical application to the skin comprising: water , a water-miscible organic solvent , 2.5% w/w benzoyl peroxide , 1.2% w/w clindamycin phosphate and a gelling agent , the gel formulation comprising a suspension of benzoyl peroxide in a saturated solution of benzoyl peroxide , in which the concentration of the water-miscible organic solvent is between one and four times the concentration of the benzoyl peroxide , and in which the ratio of the water to the water-miscible organic solvent is at least 12:1.2. The formulation of claim 1 , in which the clindamycin phosphate is dissolved in the formulation.3. The formulation of claim 2 , in which the water-miscible organic solvent is propylene glycol.4. The formulation of claim 3 , in which the concentration of the water-miscible organic solvent is two times the concentration of the benzoyl peroxide.5. The formulation of claim 2 , in which the gelling agent is a carboxyvinyl polymer.6. The formulation of claim 1 , in which the benzoyl peroxide has a mean particle size of between 2.5 ...

Подробнее
21-02-2019 дата публикации

FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND THEIR USES

Номер: US20190054106A1
Принадлежит:

A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions. 1. (canceled)2. A method of treating a dermatological or mucosal disorder , comprising applying a composition to a skin surface in need of treatment for the dermatological or mucosal disorder , said composition comprising:one or more antibiotic agents;at least about 50% by weight of a short chain alcohol;a polymeric agent;between about 2% and about 50% of at least one organic carrier selected from the group consisting of a polar solvent, a hydrophobic organic carrier, and a mixture thereof;an active herbal extract;a metal; andan antioxidant;wherein the composition is a surfactant free composition.3. The method of claim 2 , wherein the disorder is selected from an infection claim 2 , an inflammation claim 2 , an acne claim 2 , a rosacea claim 2 , a psoriasis claim 2 , an eczema claim 2 , and an atopic dermatitis.4. The method of claim 2 , wherein the one or more antibiotic agents comprise a tetracycline antibiotic claim 2 , or a salt claim 2 , ion claim 2 , or complex thereof.5. The method of claim 2 , wherein the one or more antibiotic agents are about 0.1% to about 5% by weight of the composition.6. The method of claim 5 , wherein the one or more antibiotic agents are about 1% by weight of the composition.7. The method of claim 5 , wherein the one or more antibiotic agents are about 5% by weight of the composition.8. The method of claim 2 , wherein the antioxidant is about 0.1% to about 10% by weight of the composition.9. The method of claim 2 , wherein the short chain alcohol comprises ethanol.10. The method of claim 2 , wherein the ...

Подробнее
05-03-2015 дата публикации

Anti-Microbial Composition

Номер: US20150064288A1
Автор: Found John
Принадлежит:

The present invention relates to an anti-microbial composition and method of use thereof. In particular, the present invention relates to an anti-microbial composition comprising farnesol and cetrimide. 115-. (canceled)16. A topical antimicrobial agent consisting essentially of:(i) a synergistic amount of farnesol and cetrimide; and(ii) benzoyl peroxide.17. The topical antimicrobial agent of claim 16 , further comprising an essential oil claim 16 , a stabilizer claim 16 , an excipient claim 16 , and/or a carrier.18. The topical antimicrobial agent of claim 17 , wherein the essential oil is sandalwood oil.19. The topical antimicrobial agent of claim 17 , wherein the topical antimicrobial agent consists of:(a) from about 0.1% to about 5.0% of farnesol;(b) from about 0.1% to about 5.0% of cetrimide;(c) from about 2% to about 10% of said benzoyl peroxide; and(d) from about 80% to about 97% water.20. The topical antimicrobial agent of claim 17 , wherein said stabilizer is selected from the group consisting of glyceryl monostearate claim 17 , stearic acid claim 17 , triethanolamne claim 17 , ethanol claim 17 , polysorbate 20 claim 17 , cetyl alcohol claim 17 , stearyl alcohol claim 17 , cetrimonium bromide claim 17 , citric acid claim 17 , cyclomethicone claim 17 , dimethicone claim 17 , ceteth 20 claim 17 , ceteareth 20 claim 17 , caprylic/capric triglycerides claim 17 , PEG 40 polyhydroxystearate claim 17 , polyvinyl pyrrolidone claim 17 , acetum claim 17 , glyceryl stearate claim 17 , xanthan gum claim 17 , geranium oil claim 17 , lavender oil claim 17 , eucalyptus oil claim 17 , tea tree oil claim 17 , lemon oil claim 17 , anise oil claim 17 , DEA cetyl phosphate claim 17 , sodium stearate claim 17 , potassium stearate claim 17 , wool alcohols claim 17 , octyl stearate claim 17 , carnauba wax claim 17 , ozokerite claim 17 , carbomer claim 17 , phenoxyethanol claim 17 , methyl parabens claim 17 , propyl parabens and mixtures thereof.21. The topical antimicrobial agent ...

Подробнее
28-02-2019 дата публикации

Encapsulation of peroxides for skin applications

Номер: US20190060245A1
Принадлежит: Arkema Inc

Encapsulated peroxide particles inhibit skin inflammation. A method of encapsulating a solid peroxide comprises dispersing solid peroxide particles (e.g., benzoyl peroxide) in an aqueous dispersion of fatty acid salt to form a peroxide/fatty acid salt dispersion, wherein the peroxide particles have a mean particle size (D50) of 10 μm or less; and subsequently encapsulating the solid peroxide particles by reacting the one or more monovalent fatty acid salts with one or more multivalent salts of calcium, magnesium, aluminum, silver, and/or zinc, thereby forming encapsulated peroxide particles.

Подробнее
28-02-2019 дата публикации

DISINFECTANT AGENT

Номер: US20190060270A1
Автор: Reichwagen Sven
Принадлежит: Mavena International AG

The invention relates to an agent for the disinfection of body surfaces and the destruction of bacterial metabolic products on body surfaces, said agent containing in aqueous solution at least one percarboxylic acid together with a polyvinylpyrrolidone as stabilizing agent. 1. Agent for the disinfection of body surfaces and the destruction of bacterial metabolic products , said agent containing at least one percarboxylic acid together with a stabilizing agent in aqueous solution , characterized in that polyvinylpyrrolidone (PVP) is used as stabilizing agent.2. Agent according to claim 1 , characterized in that the PVP has an average molecular weight ranging between 10 claim 1 ,000 and 360 claim 1 ,000 daltons.3. Agent according to claim 2 , characterized in that the PVP has an average molecular weight of 40 claim 2 ,000 daltons.4. Agent according to claim 1 , characterized in that the percarboxylic acid is a monocarboxylic acid claim 1 , in particular benzoic acid.5. Agent according to claim 1 , characterized in that the percarboxylic acid is a hydroxypercarboxylic acid.6. Agent according to claim 5 , characterized in that the percarboxylic acid is perlactic acid claim 5 , percitric acid claim 5 , permalic acid or pertartaric acid.7. Agent according to claim 1 , characterized in that the weight ratio of percarboxylic acid with respect to PVP is in the range of between 1:10 and 10:1.8. Agent according to claim 1 , characterized in that the aqueous solution contains 0.1 to 50% w/w claim 1 , preferably 1 to 25% w/w claim 1 , of percarboxylic acid stabilized with PVP.9. Agent according to claim 1 , characterized in that it also contains an oxidation-stable surfactant.10. Agent according to claim 9 , characterized in that it contains 0.5 to 5% w/w of polysorbate.11. Agent according to claim 1 , characterized in that it also contains a humectant.12. Use of the agent in accordance with for skin disinfection purposes.13. Use of the agent according to for the destruction of ...

Подробнее
22-05-2014 дата публикации

Foamable Benzoyl Peroxide Compositions for Topical Administration

Номер: US20140140937A1
Принадлежит: Precision Dermatology, Inc.

Described herein are benzoyl peroxide compositions useful in the treatment of acne and other skin conditions, which exhibit enhanced stability, even under accelerated conditions. The compositions also exhibit reduced color formation, reduced irritation, and enhanced moisturizing properties. They can be formulated into a topical aerosol foam with inert, non-flammable propellants, such as hydrofluoroalkanes, and may be used in cosmetics or pharmaceuticals. Additionally, methods of formulating these compositions are described. 1. A method , comprising the steps ofcombining water, glycerol, propylene glycol, methylparaben, propyl paraben, citric acid, sodium citrate, and disodium EDTA in a first container, thereby making an aqueous mixture;heating the aqueous mixture until the aqueous mixture reaches about 70° C. to about 75° C., thereby forming an aqueous solution;{'sub': 12', '15, 'combining cetostearyl alcohol, emulsifying wax, steareth-10, dimethicone, C-Calkyl benzoates, and butylated hydroxytoluene in a second container, thereby forming a nonaqueous mixture;'}heating the nonaqueous mixture until the nonaqueous mixture reaches about 70° C. to about 75° C., thereby forming a nonaqueous solution;combining the aqueous solution and the nonaqueous solution, thereby forming a first mixture;cooling the first mixture until the first mixture reaches from about 40° C. to about 45° C., thereby forming a second mixture;cooling the second mixture until the second mixture reaches about 30° C., thereby forming a third mixture;adding benzoyl peroxide to the third mixture, thereby forming a fourth mixture;stirring the fourth mixture;optionally homogenizing the fourth mixture;placing the fourth mixture in an aerosol container; andadding a propellant to the aerosol container, wherein the propellant is a hydrofluoroalkane, thereby forming an aerosol composition.2. The method of claim 1 , further comprising the step of purging the aerosol container with an inert gas claim 1 , wherein ...

Подробнее
17-03-2022 дата публикации

COMPOSITIONS AND METHODS FOR TREATING ACNE VULGARIS

Номер: US20220079958A1
Принадлежит: Dermala, Inc.

Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of acne vulgaris. The compositions include succinic acid and an API selected from the group consisting of salicylic acid, azelaic acid, picolinic acid, benzoyl peroxide, antibiotic, retinoid and combinations thereof in a pharmaceutically acceptable preparation. The compositions that include the combination of succinic acid and another API produce improved efficacy in treating acne vulgaris. 1Propionibacterium acnesP. acnesP. acnes. A method of killing a () that is resistant to an antibiotic , the method comprising treating the with a composition comprising succinic acid , wherein the succinic acid is at a concentration of at least 15 mM.231P. acnes. The method of claim , wherein the is on skin of a subject having acne vulgaris and the composition is a topical composition.331P. acnes. The method of claim , wherein the is resistant to erythromycin , clindamycin , minocycline , doxycycline , or any combination thereof.431P. acnes. The method of claim , wherein the is resistant to erythromycin , clindamycin , minocycline and doxycycline.531. The method of claim , wherein the composition further comprises azelaic acid.631. The method of claim , wherein the composition further comprises picolinic acid.731. The method of claim , wherein the composition further comprises benzoyl peroxide.831. The method of claim , wherein the composition further comprises an antibiotic.931. The method of claim , wherein the composition further comprises salicylic acid.1039. The method of claim , wherein the salicylic acid is present at concentration from 0.1 to 5%.1139. The method of claim , wherein the succinic acid is present at concentration from 0.1 to 10%.1239. The method of claim , wherein the salicylic acid and succinic acid present in a 1:2 ratio.1332. The method of claim , wherein the topical composition further comprises aloe vera , propanediol , ...

Подробнее
27-02-2020 дата публикации

METHODS FOR TREATING OR PREVENTING FATIGUE

Номер: US20200061017A1
Принадлежит:

The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments. 115-. (canceled)17. The method of claim 16 , wherein the subject is a human.18. The method of claim 16 , wherein the compound is administered orally.19. The method of claim 16 , wherein the compound is formulated with a pharmaceutical carrier.20. The method of claim 19 , wherein the pharmaceutical carrier comprises a thickening agent and a lubricant.21. The method of claim 20 , wherein the thickening agent is hydroxypropyl cellulose.22. The method of claim 16 , wherein the treatment effective amount of the compound is from about 0.01 mg/kg/dose to about 300 mg/kg/dose.23. The method of claim 16 , wherein the compound is administered concurrently with an additional agent or treatment.24. The method of claim 16 , wherein the fatigue is associated with cancer.25. The method of claim 16 , wherein the fatigue is associated with multiple sclerosis. The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.Fatigue is a weariness or lack of energy that is generally not relieved by rest or sleep. Fatigue is a common side effect of many diseases and conditions, including depression, cancer, multiple sclerosis, Parkinson's disease, Alzheimer's disease, chronic fatigue syndrome, fibromyalgia, chronic pain, traumatic brain injury, AIDS, and osteoarthritis. Fatigue can also result from administration of some medications or therapies, such as chemotherapy, radiation therapy, bone marrow transplant, and anti-depressant medications. There have been few reports of effective treatments for fatigue.The present invention provides improved methods for treating o preventing fatigue, e.g., fatigue associated with diseases or treatments.The present invention provides methods of treating and/or preventing ...

Подробнее
08-03-2018 дата публикации

LIPID CONTAINING FORMULATIONS

Номер: US20180065918A1
Принадлежит: Arbutus Biopharma Corporation

Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described. 3. A preparation comprising a compound of .4. An association complex comprising a preparation of .5. An association complex comprising a preparation of .6. The association complex of claim 4 , further comprising a therapeutic agent.7. The association complex of claim 6 , wherein the therapeutic agent is nucleic acid.8. The association complex of claim 6 , wherein the therapeutic agent is siRNA.9. The association complex of claim 6 , wherein the therapeutic agent is mRNA.10. The association complex of claim 5 , further comprising a therapeutic agent.11. The association complex of claim 10 , wherein the therapeutic agent is nucleic acid.12. The association complex of claim 10 , wherein the therapeutic agent is siRNA.13. The association complex of claim 10 , wherein the therapeutic agent is mRNA.14. A method of treating a mammal comprising administering to said mammal a therapeutic amount of an association complex of .15. A method of treating a mammal comprising administering to said mammal a therapeutic amount of an association complex of . This application is a Continuation application of U.S. patent application Ser. No. 14/149,496, filed on Jan. 7, 2014, which is a Divisional application of U.S. patent application Ser. No. 13/211,094, filed on Aug. 16, 2011, issued as U.S. Pat. No. 8,642,076 on Feb. 4, 2014, which is a continuation application of U.S. patent application Ser. No. 12/056,230, filed on Mar. 26, 2008, issued as U.S. Pat. No. 8,034,376 on Oct. 11, 2011, which is a continuation application of International Patent Application No. PCT/US2007/080331, filed on Oct. 3, 2007, which claims priority to U.S. Provisional Application No. 60/828,022 filed on Oct. 3, 2006 and U.S. Provisional Application No. 60/870,457 filed on Dec. 18, 2006. The entire content of each of these applications is hereby ...

Подробнее